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ABSTRACT

Alpha-synuclein (Snca) is a small cytosolic protein that is ubiquitously expressed in the
nervous system and comprises 0.5-1% of all cytosolic protein, but its biological function
is poorly understood. Although Snca function has been studied in lipid metabolism, the
function of Snca in brain lipid metabolism under inflammatory conditions is yet to be
elucidated. We utilized several model systems including primary cultured astrocytes and
microglia, Snca deficient and mutant knock-in mice, and a radiolabeled free fatty acid
steady state-kinetic mouse model to determine Snca role in neuroinflammation. Herein,
we have determined several major roles of Snca during inflammation: (i) dBcAMP
treatment increases 20:4n-6 uptake in astrocytes and this increase appears to be due to
increased expression of long chain acyl-CoA synthetases 3 and -4 coupled with a
reduction in acyl-CoA hydrolase expression in the presence of reduced Snca
expression. (ii) Snca deficient mice have higher basal brain 2-arachidonyl glycerol (2AG) levels compared to wildtype and lipopolysaccharide (LPS) stimulation further
exacerbated 2-AG synthesis.(iii) In primary microglia, LPS-treatment reduced released
2-AG into medium concomitantly with reduced Snca expression and Snca deficient
microglia had a delayed response to LPS stimuli. This supports the hypothesis that
Snca expression is linked to 2-AG release in primary microglia and may contribute to
regulating the phagocytic phenotype.(iv) Using Snca gene-ablated mice, we determined
the impact of Snca on brain 20:4n-6 metabolism during LPS-induced inflammatory
response in vivo using an established steady-state kinetic model. In Snca deficient
mouse brain, 20:4n-6 uptake was significantly increased 1.3-fold. In the organic fraction,
xvi

tracer entering into Snca deficient mouse total brain phospholipids was significantly
increased 1.4-fold, accounted for by increased incorporation into choline
glycerophospholipids and phosphatidylinositol. In the neutral lipid fraction, 20:4n-6
incorporation into diacylglycerol of Snca deficient mice was significantly reduced by
75%. Hence, under inflammatory conditions where 20:4n-6 release is enhanced, Snca
has a crucial role in modulating 20:4n-6 metabolism, and the absence of Snca results in
increased uptake and incorporation into lipid pools associated with enhanced lipidmediated signaling during neuroinflammatory response. Herein, we focus on the role of
Snca in downstream eicosanoid biosynthesis, inflammatory mediators, and lipid
signaling molecules linking Snca to inflammatory response elucidating a key step in
neuroinflammation.
.

xvii

CHAPTER I
INTRODUCTION
Snca and Parkinson’s disease
Snca is a 140-amino acid intrinsically unfolded protein which comprises 0.1-1%
of all brain cytosolic proteins and is predominantly found in the nervous system (Jakes et
al. 1994). Snca is an in intrinsically disordered protein but upon binding the lipid bilayers
its N-terminus develops an amphipathic helical structure. The C-terminal tail however,
remains disordered (Ahn et al. 2002). Snca is ubiquitously expressed in neurons
(Krüger et al. 2000), astrocytes (Castagnet et al. 2005), microglia (Austin et al. 2011),
and oligodendroglia (Richter-Landsberg et al. 2000). Snca is highly conserved in
vertebrates and was originally studied in neurons due to its predominate presynaptic
localization in neurons (Adamczyk et al. 2005; Raghavan et al. 2004). This has led Snca
to be highly studied in regards to its function in neurons and neurodegenerative
diseases.
A widely accepted hallmark of Parkinson’s disease (PD) and of other
synucleinopathies is the accumulation of aggregated Snca in plaques known as Lewy
bodies (Iseki et al. 1998). PD is the second most common neurodegenerative disorder
in the United States affecting nearly 3% of individuals over the age of 65 (Kowal et al.
2013). Rare familial missense mutations (A30P, A53T, E46K, H50Q, or G51D) or
multiple gene replications in Snca result in early onset PD (Krüger et al. 2000;
Polymeropoulos et al. 1997) suggesting Snca plays a key role in PD pathogenesis. PD
however, is not the only disorder that has been linked to Snca aggregation named
1

“synucleinopathies”, as Lewy bodies which are commonly found in patients with
dementia and glia in multiple system atrophy contain Snca fibrils (Farrer et al. 1999).
Although Snca function in neurons has been studied by others, we have focused on
Snca lipid mediating effects in the nervous system. Snca has a robust impact on lipid
metabolism and lipid mediated signaling having a critical role in neuroinflammation found
in neurodegenerative disorders including PD.
Snca has several diverse roles in the nervous system including synaptic
vesicular movement (Cabin et al. 2002), dopamine transporter modulation (Lee et al.
2001), and regulation of dopamine levels (Lotharius and Brundin 2002). However, recent
studies suggest Snca has a role in brain fatty acid metabolism. Previous research
suggested that Snca is a fatty acid binding protein (FABP) due to similar protein
homology and structure (Sharon et al. 2001). Although Snca facilitated fatty acid uptake
its binding constant for fatty acids is two orders of magnitude less than a classical FABP
and its impact on lipid metabolism is clearly different (Murphy et al. 2005; BarcelóCoblijn et al. 2007; Martin et al. 2003). However, like FABP (Murphy et al. 2005), Snca
increases long chain acyl-CoA synthetase (Acsl) activity, but this effect is limited to
arachidonic acid but hypothesized to affect other acyl-CoA formation (Golovko et al.
2006a). Effects of Snca on lipid metabolism are brain specific and it is hypothesized that
Snca directly modulates Acsl activity. Furthermore, Snca deficiency results in decreased
palmitic acid (PAM) and arachidonic acid (ARA) uptake, incorporation rate and fractional
turnover in PL (Golovko et al. 2005; Golovko et al. 2006a). However, in PAM infusion
studies, incorporation into choline glycerophospholipids (ChoGpl) is increased while
incorporation and turnover into all other major phospholipids are reduced (Golovko et al.
2005). Furthermore, in Snca deficient microglia n-butanol treatment partially attenuates
phospholipase D (PLD)-dependent signaling resulting in increased cytokines and
1

cytosolic phospholipase A2 (cPLA2) and cyclooxygenase 2 (Cox-2) protein levels (Austin
et al. 2011). This finding is significant because it suggests Snca affects PLD function,
which is crucial in inflammatory response and has a pivotal role in PD progression. Our
data supports this idea through increased ChoGpl recycling by increased PLD activity in
the absence of Snca as well as increased prostaglandin formation resulting from
dysfunctional ARA metabolism. Although Snca function has been studied in lipid
metabolism, the function of Snca in lipid metabolism and microglia following LPS
stimulation remains to be elucidated. This contribution is significant because it will
identify key roles of Snca in ARA metabolism as well as modulation of microglia
phenotype in neuroinflammatory response.
Our group has shown that Snca facilitates PAM and ARA uptake in astrocytes
(Castagnet et al. 2005) and brain (Golovko et al. 2005; Golovko et al. 2006a), as well as
playing a role in brain neutral lipid metabolism (Barceló-Coblijn et al. 2007). We have
established that Snca deficiency results in a marked reduction in PAM and ARA
incorporation and turnover kinetics using a steady-state kinetic model. Interestingly,
Snca deficient brain microsomes have decreased Acsl activity and incubation with
physiological levels of recombinant Snca restored this activity (Golovko et al. 2006a).
However, mutant forms (A53T and A30P) failed to restore activity. Basal prostanoid
levels are not affected by Snca ablation. However, Under ischemic conditions Snca
gene ablation results in increased formation of prostaglandins (PG) (Golovko and
Murphy 2008), demonstrating a lipid mediated link to the inflammatory response.
Although Snca affects fatty acid uptake and modulates trafficking into specific
lipid pools in vivo, the function of Snca during neuroinflammatory response is poorly
defined. Because Snca activity is crucial in brain fatty acid uptake, phospholipid fatty
acid turnover and fatty acid trafficking into specific lipid pools, it is important to asses if
2

Snca has a role in brain inflammation. Our objective is to determine the significance
Snca expression in vivo on ARA uptake and trafficking into lipid pools following LPS (i.p.)
stimulation. The arachidonic acid infusion following LPS stimulation will apply a welldefined radiotracer steady-state kinetic model to determine fatty acid uptake and
turnover (Robinson et al. 1992). The rationale for this is that Snca is known to affect
brain fatty acid uptake and trafficking into specific lipid pools by modulating ER-localized
Acsl activity (Golovko et al. 2006a). Snca binds free fatty acids at a low Kd, but does not
target fatty acids for β-oxidation, or produce a change in lipid mass after gene ablation
suggesting it does not act as a FABP(Golovko et al. 2006a). Interestingly though, Snca
has been hypothesized to have these similar roles of a FABP by enhancing ER-based
lipid synthetic enzyme activity (Golovko et al. 2006a).
ARA and PAM are prepared for utilization by the addition of CoA by Acsl, which
in turn allows the FA-CoA to participate in biosynthetic or catabolic pathways. There are
five long chain acyl-CoA synthetase isoforms in humans and rodents (Watkins et al.
2007). These isoforms differ in their substrate preferences, regulation, enzyme kinetics,
alternative splicing and location. Of these 5 isotypes Acsl-4 and-6 are prominently found
in the brain (Cao et al. 2000; Kee et al. 2003; Van Horn et al. 2005). Acsl-6 is
alternatively spliced into four variants Acsl-6v.1-4 (Van Horn et al. 2005; Lee et al.
2005b). Acsl-4 presents high affinity for PAM and Acsl-6v.1 shows high affinity for ARA.
Incubation with wildtype, but not mutant forms of Snca (A53T and A30P) recombinant
protein restores Acsl activity to make ARA-CoA in isolated gene deficient microsomes
from Snca ablated mice (Golovko et al. 2006a). This lack of Acsl modulation by the
mutants gives reason to believe that mutant forms function like the null. However, the
role of hSnca and its mutant forms on Acsl activity and fatty acid uptake and trafficking is
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unknown. Furthermore, Snca ablation has shown a significant decrease in phospholipid
targeting in PAM treated mice (Barceló-Coblijn et al. 2007; Golovko et al. 2005).
However, incorporation of PAM into ChoGpl is increased possibly due to increased
activity of PLD2 resulting in increased ChoGpl turnover. This increase in turnover should
also be reflected in mutant Snca expressing mice, directly linking mutant Snca
dysfunction to lipid signal transduction. Hence, these data contributes an important
missing, yet fundamental element in Snca physiology. Acquisition of this knowledge is
crucial to understanding the fundamental roles of Snca not only in PD, but to a broad
spectrum of CNS disease that result in neurodegeneration. We expect to determine if
Snca has an important role in facilitating fatty acid uptake and trafficking in phospholipid
pools during neuroinflammation. Such a finding is important because it illuminates key
functions of a ubiquitously expressed, yet poorly defined, protein that is established as
the center of all synucleinopathy type neurodegenerative diseases.
Progressive Parkinson’s disease is associated with the presence of activated
microglia and neuroinflammation (Austin et al. 2006; Teismann and Schulz 2004). Snca
inhibits PLD activity in yeast (Outeiro and Lindquist 2003) as well as in animal studies
(Jenco et al. 1998). PLD activity is essential for activation of microglia required for
inflammatory response including expression of key cytokines such as IL-1 and TNF-α
(Austin et al. 2011). Similarly, dysfunctional ARA metabolism in Snca ablated mice
results in increased prostaglandin biosynthesis (Golovko and Murphy 2008).
Furthermore, Snca stimulates PLCβ (Narayanan et al. 2005), which in turn generates
diacylglycerol which can then be hydrolyzed by diacylglycerol lipase to produce 2arachidonyl glycerol (2-AG) (Blankman et al. 2007). 2-arachidonyl glycerol is important
in both microglia motility and phenotypic state (Walter et al. 2003). However, it is
unknown if Snca have a similar effect on 2-AG levels and subsequent
4

neuroinflammation. LPS treatment is needed because Snca deficient mice display a
basal inflammatory profile similar to wild type. However, during inflammatory insult, such
as LPS treatment, the depressed PLD2 inhibition and ability to recycle ARA result in an
increased inflammatory profile. Our rationale is that Snca is known to affect ARA
metabolism producing inflammatory metabolites as well as PLD2 and PLCβ activity
modulation by Snca, would produce key players in lipid signal transduction. Snca
deletion increases prostaglandin formation after ischemic injury, suggests that Snca has
a role in brain response to injury and inflammation (Golovko and Murphy 2008). The
increased prostaglandin profile and reduced Acsl activity is consistent with reduced
ARA-CoA turnover causing increased ARA release into the free FA pool and subsequent
metabolism into eicosanoids. An increase in downstream inflammatory mediators and
cytokines released in microglia suggests involvement of PLD2 activity (Austin et al.
2011). Increased turnover of ChoGpl found in Snca deficient mouse brain is consistent
with tonic inhibition of PLD2 by Snca (Jenco et al. 1998). Furthermore, butanol treatment
attenuates PLD-mediated generation of phosphatidic acid (PA), by
transphosphatidylation of ChoGpl into phosphatidylbutonal causing a resultant drop in
PA release, is consistent with reduced cytokine secretion observed in gene ablated
microglia (Austin et al. 2011). Herein, we focus on the role of Snca in downstream
eicosanoid biosynthesis, inflammatory mediators, and lipid signaling molecules linking
Snca to inflammatory response elucidating a key step in neuroinflammation
In this manuscript I will present several lines of evidence indicating that Snca
plays a vital role in brain lipid metabolism and has an impact on the inflammatory state of
the brain. I will utilize several model systems including primary cultured astrocytes and
microglia, Snca deficient and Snca mutant knock-in mice, and a radiolabeled free fatty
acid steady state-kinetic mouse model to determine the role of Snca in
5

neuroinflammation. In chapter I, I will determine how phenotypic shift of astrocytes by
dBcAMP affects PAM and ARA uptake and trafficking and expression of enzymes that
regulate these changes. This is important because astrocyte-derived lipids are critical in
brain function and dBcAMP treatment results in an activated phenotype in astrocytes
similar to what is found in neuroinflammation. In chapter II, Because Snca affects ARA
metabolism, we will determine whole brain 2-AG levels in wild type, Snca gene-ablated,
and Snca knock-in animals at basal levels and following LPS stimulation. This is
important because 2-AG is synthesized from ARA containing DAG and is a
neuroprotective bioactive lipid that plays a role in lipid signal transduction and can
modulate inflammatory response. In chapter III, using primary microglia we will
determine how 2-AG levels are related to Snca expression. This is important because,
2-AG affects microglia motility and 2-AG levels may contribute to the reduced phagocytic
ability found in Snca deficient microglia. Finally in chapter IV, we will determine the
impact of Snca deficiency on brain ARA metabolism during LPS-induced inflammatory
response in vivo using an established steady-state kinetic model. This is important
because, under inflammatory conditions where ARA release is enhanced, Snca has a
crucial role in modulating 20:4n-6 uptake and incorporation into lipid pools associated
with lipid-mediated signaling and may enhance fatty acid uptake and metabolism during
neuroinflammatory response. In the following chapters we will elucidate the role of Snca
in lipid metabolism and downstream neuroinflammatory mediators.
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CHAPTER II
INTRODUCTION
Arachidonate and palmitate uptake and metabolism is differentially modulated by
dibutyryl-cAMP treatment
Brain injury results in astrocytosis, a process that involves activation of
astrocytes within hours after injury and this activation is sustained for weeks following
injury (Csuka et al. 2000; Bye et al. 2011). In cultured astrocytes, treatment with
dibutyryl-cAMP (dBcAMP), a cell permeable cAMP analog, induces a phenotypic shift to
a fibrous morphology characteristic of a reactive astrocyte (Fedoroff et al. 1987; Fedoroff
et al. 1984; Miller and Raff 1984) and is similar to activated astrocytes following
traumatic brain injury. Consistent with this phenotype, dBcAMP treated astrocytes
express increased levels of glial fibrillary acidic protein (Bignami and Dahl 1976) and
vimentin (Ciesielski-Treska et al. 1984) as well as broad changes in modulation of
protein phosphorylation (Neary et al. 1987). In dBcAMP treated astrocytes, actin is
reorganized (Goldman and Abramson 1990; Ciesielski-Treska et al. 1984) with an
increased number of tightly packed intermediate filaments (Goldman and Chiu 1984)
and microfilament ring formation (Fedoroff et al. 1987), producing stellate processes that
are a hallmark of reactive astrocytes in vivo. Although astrocytosis has been highly
studied in central nervous system (CNS) trauma, ischemia, and stroke using dBcAMP
treated astrocytes, differences in fatty acid metabolism between non-treated and
dBcAMP treated primary astrocytes are poorly defined.

9

Astrocytes have a crucial role in brain cholesterol metabolism and overall CNS
function. Apolipoprotein E (ApoE) is synthesized in the central nervous system and is
predominantly expressed in astrocytes (Boyles et al. 1985; Elshourbagy et al. 1985; Krul
and Tang 1992). Although, ApoE and B receptors are expressed on astrocyte endfeet
near the arachnoid space (Pitas et al. 1987), it is widely accepted that plasma-derived
ApoE lipoprotein containing cholesterol does not cross the blood-brain barrier and
cholesterol within the CNS is a result of synthesis in astrocytes de novo (Dietschy et al.
1983; Dietschy and Turley 2001; Osono et al. 1995; Hanaka et al. 2000). ApoE with
bound cholesterol is released by cultured astrocytes (Krul and Tang 1992; Boyles et al.
1985), which is important as it combines ApoE and cholesterol production in the same
cell. Neurons normally express low-density lipoprotein receptors (LDLR) (Swanson et al.
1988; Motoi et al. 1999; Beffert et al. 2004), which stimulate axonal growth and
synaptogenesis (Hayashi et al. 2004; Mauch et al. 2001). However, after injury and
during neuronal repair, neurons have increased expression of LDLR on growth cones
and rely on ApoE derived cholesterol for remodeling (Poirier et al. 1993; Ignatius et al.
1987; Swanson et al. 1988; Posse de Chaves et al. 1997; Krul and Tang 1992; Yin et al.
2012). Interestingly, in transgenic mice expressing human ApoE, purified human ApoE
contains abundant ethanolamine glycerophospholipids (EtnGpl) and choline
glycerophospholipids (ChoGpl), as well as cholesterol (DeMattos et al. 2001),
suggesting phospholipids are also taken up by neurons via ApoE/LDLR mechanisms
(Staub et al. 1995; Moore et al. 1991; Bernoud et al. 1998).
Fatty acid binding proteins (FABP) act as fatty acid chaperons that facilitate fatty
acid uptake and targeting (Murphy 1998; Murphy et al. 1996; Prows et al. 1995; Binas et
al. 1999; Murphy et al. 2004; Murphy et al. 2005) and also affect cellular phospholipid
10

metabolism (Murphy et al. 2004; Murphy et al. 2005; Murphy et al. 2000a; Jolly and
Murphy 2002). The brain expresses three different fatty acid binding proteins, FABP3,
FABP5, and FABP7 (Owada and Kondo 2003; Owada et al. 1996; Owada 2008;
Veerkamp and Zimmerman). FABP7 is developmentally expressed in radial glial cells
(Kurtz et al. 1994; Owada et al. 1996) and is then expressed at lower levels in adult
mouse astrocytes (Myers-Payne et al. 1996; Owada et al. 1996). It has a preference for
binding of the n-3 fatty acid family (Myers-Payne et al. 1996; Feng et al. 1994). FABP7
may serve as a plasma derived biomarker useful for diagnosing patients with dementiarelated diseases, such as Alzheimer’s and Parkinson’s disease (Teunissen et al. 2011).
FABP5 is expressed primarily in gray matter in glial cells, although there does appear to
be limited expression in white matter, in the adult animal (Owada et al. 1996). FABP5
has less specificity and impacts both n-3 and n-6 fatty acid uptake into the cell and
spinal cord (Liu et al. 2008; Figueroa et al. 2016). In PC-12 cells it enhances neurite
extension (Allen et al. 2000) and protects cells from lipotoxicity through a potential NFκB
mechanism (Liu et al. 2015). FABP3 is expressed in the brain primarily in neurons, with
the highest expression in cortical layers, in hippocampus, and in dentate gyrus (Owada
et al. 1996; Sellner et al. 1995). FABP3 has a binding preference for n-6 fatty acids
(Hanhoff et al. 2002), suggesting that this protein may be involved in neuronal 20:4n-6
uptake and trafficking.
Arachidonic acid (20:4n-6) is highly esterified into ethanolamine
glycerophospholipids (EtnGpl) and its biosynthesis can occur within astrocytes, which
may be crucial for maintaining brain 20:4n-6 levels in brain signal transduction events
(Moore et al. 1991). Although neurons and blood-brain barrier endothelium are capable
of elongation and desaturation of fatty acids, the bulk of 20:4n-6 is provided through
11

plasma derived 20:4n-6 or by that provided by astrocytes (Moore et al. 1991; Bernoud et
al. 1998; Rapoport et al. 2001). Cultured astrocytes can either take up 20:4n-6 or
synthesize it from linoleic acid (18:2n-6) and subsequently esterify it into lipid pools
following activation by formation of its CoA thioester, which is catalyzed by long chain
acyl-CoA synthetases (Acsl). Astrocytes readily take up the precursor of 20:4n-6,18:2n6, which is preferentially elongated and desaturated into 20:4n-6, resulting in increased
20:4n-6 incorporation into phospholipid pools (Williard et al. 2002; Murphy 1995). This is
important because 20:4n-6 is the major polyunsaturated fatty acid (PUFA) at the sn-2
position in EtnGpl and ChoGpl (Svennerholm 1968; Murphy 1984; López et al. 1995).
These phospholipid pools are reservoirs for 20:4n-6 that can be directly released as free
fatty acids (FFA) by Ca+2 –dependent activation of PLA2, via inositide signal transduction
pathways, resulting in 20:4n-6 release from phospholipids (Wilkin et al. 1991) and
subsequent metabolization into prostanoids exerting a downstream signal (Keller et al.
1987; Strokin et al. 2003). Treating astrocytes with dBcAMP causes a substantial
increase in elongation and desaturation pathway and increase in 20:4n-6 mass,
suggesting a larger releasable pool of 20:4n-6 (Murphy et al. 1997). Thus, events
regulating 20:4n-6 metabolism have a major role in CNS function and understanding the
modulation of 20:4n-6 in phenotypically shifted astrocytes is crucial to understanding the
changes in 20:4n-6 uptake and trafficking in reactive astrocytes.
Because dBcAMP treated astrocytes show phenotypic similarities to reactive
astrocytes and 20:4n-6 metabolism is crucial during events associated with astrocytosis,
we examined the impact of dBcAMP phenotypic shift on 20:4n-6 uptake into astrocytes
and its incorporation into lipid pools. A predominately sn-1 position fatty acid, palmitic
acid (16:0), was used to determine the potential changes in sn-1 position fatty acid
12

metabolism. dBcAMP treatment specifically increased 20:4n-6 uptake and incorporation
into phospholipid pools, while 16:0 uptake was unaffected. Interestingly, Acsl gene
expression was effected by dBcAMP treatment. We demonstrate for the first time that in
dBcAMP treated astrocytes, 20:4n-6 uptake and incorporation was enhanced,
suggesting that dBcAMP had a significant impact on 20:4n-6 metabolism via modulation
of Acsl expression in astrocytes and potentially impacts 20:4n-6 use in downstream
signal transduction (Seeger et al. 2016).
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MATERIALS AND METHODS
Cells
Mouse cortical astrocytes were isolated from brains of 1 day old 129/SvEv mice
under an approved protocol by the University of North Dakota (Grand Forks, ND) Animal
Care and Use Committee (UND protocol #1106-1C). Cortices were triturated in
Dulbecco’s modified Eagle’s medium (DMEM) to separate cells, filtered through 80 µm
Nylon mesh, and resuspended in DMEM containing 10% fetal bovine serum (FBS).
Astrocytes were cultured in DMEM containing 10% FBS, 3.7 g/L bicarbonate, 2 mM
glutamine, 100 µg/mL penicillin/streptomycin, and 5 mM HEPES at pH 7.4 in a water
jacketed incubator at 37°C in 5% CO2 atmosphere. Astrocytes were expanded by
subculturing on T-75 flasks (4:1) by loosening the adherent cells with 0.25% trypsin.
The third passage (3:1) was plated on 100 mm polystyrene cell culture plates prior to
treatment with dBcAMP. Confluent astrocytes were treated with 0.25 mM dibutyryl-cAMP
in serum containing medium for a period of four days prior to incubation with fatty acid
radiotracers (Hertz 1990; Murphy et al. 1997). Because changes in phospholipid fatty
acid composition occur in primary astrocytes over time, cells in this study were
subcultured for more than 28 days in culture (Murphy et al. 1997).
Fatty Acid Incubation
The effect of dBcAMP treatment on fatty acid uptake and trafficking in primary
cortical astrocyte cultures was determined by incubating the cells with 2 µM [114

C]20:4n-6 or 2 µM [1-14C]16:0 (Moravek Biochemicals, Brea, CA, USA) in FBS-free

DMEM. These concentrations are well below the critical micellar concentration for each
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fatty acid. Tracers were dissolved in ethanol and the final concentration of ethanol added
to the culture was < 0.2% (Castagnet et al. 2005). The final tracer specific activity was
4.87 nCi/nmol for [1-14C]20:4n-6 and 4.73 nCi/nmol for [1-14C]16:0, which was used to
calculate the mass of tracer taken up into cells. Astrocytes were incubated with fatty
acids for 1, 5, 15, and 30 min at 37°C in 5% CO2.
Lipid Extraction
Prior to cell lipid extraction, FBS free-DMEM was removed and cells were rinsed twice
with 2 mL of ice cold phosphate buffered saline (PBS) to remove residual tracer and
medium (Murphy et al. 1997). The plate was then immediately floated on liquid nitrogen
to stop enzymatic activity and 2 mL of 2-propanol added. Then the cells were removed
from the plate using a Nylon cell scraper and the 2-propanol containing the cellular
debris was then transferred to a test tube containing 6 mL of hexane (Murphy et al.
1997; Castagnet et al. 2005). The plate was then washed using a second addition of 2propanol, which was added to the tube contain the first aliquot of 2-propanol resulting in
a solution of n-hexane:2-propanol (HIP 3:2 v/v) (Radin 1988). Cell extracts were then
dried under N2(g) until ~1 ml of the solvent remained. The extracts were then subjected
to centrifugation (3,000xg) for 20 minutes at 4°C to the pellet cellular debris and
denatured protein. The lipid containing supernatant was decanted and saved for
analysis. Cellular debris was washed with 2 ml HIP (3:2 v/v) and the debris pelleted by
centrifugation (3,000x g) and the wash combined with the initial extract. The debris
pellet containing cellular protein was air dried overnight at room temperature and saved
to quantify the protein. Lipid extracts were stored under a N2(g) atmosphere at -80°C in
HIP.
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Protein Quantification
The dried cellular debris was subjected to hydrolysis with 0.2 M KOH at 65°C overnight
(Murphy and Horrocks 1993). Proteins were then quantified using a modified dyebinding assay (Bradford 1976). Bovine serum albumin dissolved in 0.2 M KOH as a
standard and was used to convert absorbance to concentration via standard curve.
Thin Layer Chromatography
After drying the lipid extracts under N2(g) and dissolving them in chloroform (CHCl3), the
phospholipid and neutral lipid fractions were separated using silicic acid column
chromatography (Clarkson Chemical Company, Inc., Williamsport, PA, USA). The
neutral lipid fraction was eluted with chloroform:methanol (58:1 by vol) and the
phospholipid fraction eluted with methanol (Murphy et al. 1997). Radioactivity of
phospholipid and neutral lipid fractions was determined by liquid scintillation counting
after silicic acid column separation to determine a total radioactivity of each fraction.
Following fractionation, neutral and phospholipids were separated using thin-layer
chromatography (TLC) on heat-activated (110°C) Whatman silica gel-60 plates. Neutral
lipids were separated using petroleum ether:diethyl ether:acetic acid (75:25:1.3 by vol)
(Marcheselli et al. 1988). Phospholipids were separated using
chloroform:methanol:acetic acid:water (50:37.5:3:2 by vol) (Jolly et al. 1997). Bands
containing individual lipid classes were identified using commercially available standards
(Avanti, Polarlipids Alabaster, AL; NuChek Prep., Elysian, MN, USA). Samples were
then visualized using iodine (phospholipids) or 6-(p-Toluidino)-2-naphthalenesulfonic
acid (TNS) (neutral lipids) (Jones et al. 1982). Bands were removed by scraping and put
into 20 ml glass liquid scintillation vials to which 0.5 ml of H2O was added to facilitate
lipid desorption from the silica. Then 8 ml of ScintiVerse BD cocktail (Fisher Scientific,
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Pittsburg, PA, USA) was added and the samples were mixed by vortexing and were
counted 1 h after mixing to allow silica to settle using a Beckman LS 6500 liquid
scintillation counter equipped with low level detection software (Fullerton, CA, USA).
Quantitative real-time PCR
RNA was extracted from astrocytes using the Qiagen RNeasy Kit and quantified on an
Epoch spectrophotometer system (BioTek, Winooski, VT, USA). Optical density was
used to verify RNA concentration at 260 nm and genomic DNA contamination by
260/280 nm ratio. Then 2 µg of poly(A)+ RNA was used for first strand synthesis using
the iScript cDNA Synthesis Kit (Bio-Rad Hercules, CA, USA). cDNA was quantified
using a Cepheid Smart Cycler detection system with FastStart SYBR green (Roche,
Indianapolis, IN, USA) spiked with Taq DNA polymerase (New England BioLabs,
Ipswich, MA, USA). Primers used for all Acsl isoforms, Acot-7, Fabp, SDHA, and Snca
are shown in Table 1. Samples were pre-denatured (95°C for 120 s) then a polymeraseactivation program (45 cycles of 95°C for 15 s, 60-53°C for 30 s, and 72°C for 30 s) was
followed by post-annealing at 72°C for 120 s. Then a melting temperature (Tm) curve
program (60-95°C ramp at 0.2°C/s) was used to identify amplification contaminants.
Table 1. Primer sequences used for astrocyte qRT-PCR
Isoform

Forward Primer

Reverse Primer

Acsl1

CTTAAATAGCATCGCAACCCG

TCGAAAATACCGGAACAATTCATG

Acsl3

TCTGAGGAGCAGCCAGG

GGAGGCTAAGACAGATGGATC

Acsl4

TTCCTCTTAAGGCCGGGA

GTTAGTAATCTTTGGAAGCCAGC

Acsl5

CAGAAAGCCTCACTCGGAAG

AAACGTCAGGAGGCAGATC

Acsl6_v1

CTTTCCGAGACAGGACGATG

GAGCCTTCATGTCATCTGAGAG

Acsl6_v2

CGTCCACTTTTCCTACTTGCC

GGAGAGCCTTCATGTCATCTG
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Acsl6_v3

CACTTCAGCATGTGCACTTTC

CTCCTGGGTCTGCATCTTC

Acsl6_v4

GATGTGGTAACCTCTTTCCCTG

CTCCTGGGTCTGCATCTTC

Acot7

CCTCCCAGGCTCATTCA

ACATCTTGGCTGCGACG

Fabp3

ACCTGGAAGCTAGTGGACAG

TGATGGTAGTAGGCTTGGTCAT

Fabp5

CAAAACCGAGAGCACAGTGA

AAGGTGCAGACCGTCTCAGT

Fabp7

CCAGCTGGGAGAAGAGTTTG

TTTCTTTGCCATCCCACTTC

SDHA

CCTACCCGATCACATACTGTTG

AGTTGTCCTCTTCCATGTTCC

Snca

GCCCTTGCCTCTTTCATTG

GTCCTTTCATGAACACATCCATG

Table 1 continued. Primer sequences used for astrocyte qRT-PCR
A common threshold of fluorescence was set and using the absolute standard curve
method, the number of cycles (Ct) was used to determine absolute number of copies of
target gene cDNA. Endogenous control succinate dehydrogenase complex, subunit A,
(flavoprotein) SDHA, was used to normalize target gene copy number found by qRTPCR, resulting in a ratio of target gene to house-keeping gene.
Statistics
Statistical analysis was done using Instat® statistical program (Graphpad, San Diego,
CA). Multiple comparisons were assessed using a one-way ANOVA and a TukeyKramer post hoc test, with p < 0.05 considered to be significant. Where appropriate (Fig.
6, 9, 10, 11, and 12) Student’s two-tailed t-test was used to determine significance
between treatment groups, with p < 0.05 considered to be significant. Each time point
contains samples from five (n=5) individually treated separate cell cultures. For analysis
of gene-expression, n=3.
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RESULTS
dBcAMP treatment increases arachidonate but not palmitate uptake in astrocytes
dBcAMP treatment of astrocytes increased [1-14C]20:4n-6 uptake 1.9-fold
compared to non-treated astrocytes (control), while no change was observed in total [114

C]16:0 uptake (Fig. 1). Consistent with [1-14C]20:4n-6 total uptake, the rate of [1-

14

C]20:4n-6 uptake was appreciably faster in treated astrocytes (229 pmol x mg prot-1 x

min-1) as compared to non-treated astrocytes (143 pmol x mg prot-1 x min-1) between 515 min (Fig. 1). Treatment increased the rate and extent of [1-14C]20:4n-6 uptake, but
not of [1-14C]16:0 uptake, suggesting that dBcAMP treatment has an impact on specific
fatty acid uptake in astrocytes.
dBcAMP treatment differentially modulates free fatty acid metabolism
Although dBcAMP treatment enhanced the rate and extent of [1-14C]20:4n-6
uptake, we determined if it altered the distribution of fatty acid between the free fatty acid
(FFA) pool and esterified pool. In dBcAMP treated astrocytes, total esterification of [114

C]20:4n-6 was increased 2.0-fold, but there was no change in the amount of tracer in

the FFA pool (Fig. 2). However, at the initial time point (1 min), there was a slight, but
significant increase in the mass of free tracer in the FFA pool, but this increase was
rapidly shifted to the esterified pool by 5 min
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Figure 1. Effect of dBcAMP treatment on [1-14C]20:4n-6 or [1-14C]16:0 uptake in
astrocytes. Astrocytes were incubated with 2 µM radiolabeled [1-14C]20:4n-6 or
[1-14C]16:0 from 1 to 30 minutes. Untreated (Control, filled-circle) and dBcAMP treated
(dBcAMP, unfilled-circle) astrocytes were incubated with [1-14C]16:0 (upper panel) and
[1-14C]20:4n-6 (lower panel). Values represent means ± standard deviation (n=5). The
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asterisk indicates a statistically significant difference from untreated (control) to treated
(dBcAMP) astrocytes while lettering denotes statistically significant differences within
groups using a one-way ANOVA and a Tukey-Kramer post hoc test (p < 0.05).
Reproduced with permission.

Expressing these data as fractional distribution of tracer (Fig. 2), it becomes apparent
that dBcAMP treatment enhanced the movement of tracer from the free [1-14C]20:4n-6
pool to the esterified pool.
For [1-14C]16:0, there was a 1.5-fold increase in total esterified tracer,
accompanied by a profound 71% reduction in tracer entering the FFA pool in dBcAMP
treated astrocytes (Fig. 3). This large reduction in tracer found in the FFA pool of
dBcAMP treated astrocytes accounted for the lack of increased [1-14C]16:0 uptake (Fig.
1). Fractional distribution of [1-14C]16:0 was significantly different between groups (Fig.
3), which mirrors the changes in mass of fatty acid esterified, indicating that more tracer
was being targeted for esterification. Although there was no net change for total [114

C]16:0 uptake, unlike [1-14C]20:4n-6, dBcAMP treatment produce profound changes in

the distribution of [1-14C]16:0 into metabolic pools, enhancing its transfer from the FFA
pool to the esterified pool.
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Figure 2. Mass of [1-14C]20:4n-6 esterified or unesterified in dBcAMP treated and
untreated astrocytes expressed as total uptake (upper panel) and fractional distribution
(lower panel). Untreated (Control FFA, filled-square and Control Esterified, filled-circle)
and dBcAMP treated (dBcAMP FFA, unfilled-square and dBcAMP Esterified, unfilledcircle) astrocytes were incubated [1-14C]20:4n-6 from 1 to 30 minutes. Values represent
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means ± standard deviation (n=5). The asterisk indicates a statistically significant
difference from untreated (control) to treated (dBcAMP) astrocytes while lettering
denotes statistically significant differences within groups using a one-way ANOVA and a
Tukey-Kramer post hoc test (p < 0.05). Reproduced with permission.
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Figure 3. Mass of [1-14C]16:0 esterified or unesterified in dBcAMP treated and untreated
astrocytes expressed as total uptake (upper panel) and fractional distribution (lower
panel). Untreated (Control FFA, filled-square and Control Esterified, filled-circle) and
dBcAMP treated (dBcAMP FFA, unfilled-square and dBcAMP Esterified, unfilled-circle)
astrocytes were incubated with [1-14C]16:0 from 1 to 30 minutes. Values represent
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means ± standard deviation (n=5). The asterisk indicates a statistically significant
difference from untreated (control) to treated (dBcAMP) astrocytes while lettering
denotes statistically significant differences within groups using a one-way ANOVA and a
Tukey-Kramer post hoc test (p < 0.05). Reproduced with permission.

dBcAMP treatment increases esterification and trafficking of [1-14C]20:4n-6 and
[1-14C]16:0 into phospholipid pools

Because dBcAMP treatment increased the esterification of [1-14C]20:4n-6 and
[1-14C]16:0, we determined its effect on tracer movement into the phospholipid pools.
There was a significant 2.2-fold increase in the extent of [1-14C]20:4n-6 esterified into
phospholipids at 30 min in dBcAMP treated astrocytes (Fig. 4). This is consistent with
the increased rate of esterification into phospholipids of dBcAMP treated cells from 5-15
min, (191 pmol x mg prot-1 x min-1) as compared to non-treated astrocytes (158 pmol x
mg prot-1 x min-1) (Fig. 4). The fractional distribution clearly demonstrated the enhanced
rate of targeting of [1-14C]20:4n-6 to the phospholipid fraction, but both treated and nontreated astrocytes reached saturation by 15 min (Fig. 5). These data indicate that
dBcAMP treatment increased initial rate of [1-14C]20:4n-6 movement into phospholipid
pools.
Although total uptake for [1-14C]16:0 was not increased by dBcAMP treatment
(Fig. 1), more [1-14C]16:0 was esterified into phospholipids (Fig. 5), which is consistent
with the observed increase in its total esterification (Fig. 3). Interestingly, this occurred
at a nearly constant rate over the 30 min incubation and unlike [1-14C]20:4n-6
esterification did not reach saturation.
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Figure 4. Effect of dBcAMP treatment on tracer incorporation into phospholipids in
dBcAMP treated and untreated astrocytes. The extent of esterification of [1-14C]16:0
(upper panel) and [1-14C]20:4n-6 (lower panel) for untreated (Control, filled-downward
triangle) and treated (dBcAMP, unfilled-downward triangle) astrocytes from 1 to 30
minutes. Values represent means ± standard deviation (n=5). The asterisk indicates a
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statistically significant difference from untreated (control) to treated (dBcAMP) astrocytes
while lettering denotes statistically significant differences within groups using a one-way
ANOVA and a Tukey-Kramer post hoc test (p < 0.05). Reproduced with permission.

Fractional distribution of [1-14C]16:0 into phospholipids was immediately (1 min)
increased and remained enhanced at all time points over non-treated cells (Fig. 5),
indicating that dBcAMP treatment resulted in sustained increased targeting of [114

C]16:0 into the phospholipid pool. Although a similar event occurred for [1-14C]20:4n-6

(Fig. 5), only about 65% of the [1-14C]16:0 fatty acid mass was found associated with the
phospholipid pools as opposed to nearly 85% of [1-14C]20:4n-6 in treated astrocytes.
Individual phospholipid classes were similarly altered by dBcAMP treatment

Because dBcAMP treatment enhanced the extent of tracer entering the total
phospholipid pool, we determined its impact on tracer uptake into individual phospholipid
classes. At 30 min of incubation, dBcAMP treatment resulted in a marked increase in
the mass of [1-14C]20:4n-6 found in sphingomyelin (CerPCho), ChoGpl,
phosphatidylinositol (PtdIns), with an even more profound effect on the mass targeted to
EtnGpl (Fig. 6), which is consistent with the increase in total phospholipid incorporation
(Fig. 4). Interestingly, dBcAMP treated astrocytes also had increased [1-14C]20:4n-6, but
not [1-14C]16:0, incorporation into phosphatidylserine (PtdSer). Although there is a
difference between the magnitude of [1-14C]20:4n-6 and [1-14C]16:0 esterification into
individual phospholipid classes, there is a similar increase between the dBcAMP treated
astrocytes as compared to the non-treated astrocytes.
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Figure 5. Fractional distribution of tracer into phospholipid fraction in dBcAMP treated
and untreated astrocytes. The Fractional Distribution of [1-14C]16:0 (upper panel) and
[1-14C]20:4n-6 (lower panel) for untreated (Control, filled-downward triangle) and treated
(dBcAMP, unfilled-downward triangle) astrocytes from 1 to 30 minutes. Values
represent means ± standard deviation (n=5). The asterisk indicates a statistically
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significant difference from untreated (control) to treated (dBcAMP) astrocytes while
lettering denotes statistically significant differences within groups using a one-way
ANOVA and a Tukey-Kramer post hoc test (p < 0.05). Reproduced with permission.

This broad increase in targeting of tracer to individual phospholipid classes is
consistent with the increased targeting of both [1-14C]16:0 and [1-14C]20:4n-6 into the
phospholipid pool (Fig. 4), however, a more substantial increase in EtnGpl suggests that
dBcAMP treated astrocytes may be specifically targeting tracer to EtnGpl.
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Figure 6. Tracer esterification into individual phospholipids in dBcAMP treated and
untreated astrocytes. The extent of esterification of [1-14C]16:0 (upper panel) and [114

C]20:4n-6 (lower panel) for untreated (Control, filled) and treated (dBcAMP, unfilled)

astrocytes from 30 minutes. Values represent means ± standard deviation (n=5). The
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asterisk indicates a statistically significant difference from untreated (control) astrocytes
using Student’s t-test (p < 0.05). Reproduced with permission.
dBcAMP treatment alters esterification and trafficking of [1-14C]16:0 and [114
C]20:4n-6 to neutral lipids

Although the bulk of the tracer taken up in astrocytes is esterified into
phospholipids, nearly 35% and 15% of esterified [1-14C]16:0 or [1-14C]20:4n-6,
respectively, was incorporated into neutral lipids therefore, we determined the effect of
dBcAMP treatment on fatty acid trafficking into esterified neutral lipid classes. In
dBcAMP treated astrocytes, total incorporation of [1-14C]20:4n-6 into neutral lipids was
not increased at 30 min (Fig. 7) However, there was a small but significant increase in
rate between 5-15 min in treated astrocytes which shifted back to control levels by 30
min (Fig. 7). Fractional distribution of [1-14C]20:4n-6 into neutral lipids in treated
astrocytes was significantly less then untreated at 5 and 30 min, suggesting that
although minor, the amount of [1-14C]20:4n-6 being targeted to neutral lipids in dBcAMP
treated astrocytes was reduced (Fig. 8).
Although there was no net change in total uptake of [1-14C]16:0 (Fig. 1), dBcAMP
treatment resulted in a marked increase in its targeting to the neutral lipid fraction at
early time points (5-15 min), similar to the enhanced targeting of [1-14C]16:0 to
phospholipids, but returned to levels found in untreated cells by 30 min (Fig. 7). Similar
to total neutral lipid uptake, fractional distribution of tracer, indicates dBcAMP treatment
increased [1-14C]16:0 incorporation into neutral lipids at the initial time point (1 min) as a
result of rapidly transferring tracer to esterified neutral lipid and phospholipid fractions
(Fig. 8). Interestingly, incorporation and trafficking of [1-14C]16:0 in dBcAMP treated
astrocytes returns to control levels by 30 min indicating its incorporation into neutral
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lipids is saturable. While dBcAMP treatment enhanced the magnitude of tracer
esterification and the magnitude of tracer initially entering the different fractions, its
impact on the fractional distribution of the tracer into the esterified neutral lipid pool at 30
min was minor.
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Figure 7. Effect of dBcAMP treatment on tracer incorporation into neutral lipids in
dBcAMP treated and untreated astrocytes. The extent of esterification of [1-14C]16:0
(upper panel) and [1-14C]20:4n-6 (lower panel) for untreated (Control, filled-triangle) and
treated (dBcAMP, unfilled-triangle) astrocytes from 1 to 30 minutes. Unesterified free
fatty acids were not included in the neutral lipid mass. Values represent means ±
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standard deviation (n=5). The asterisk indicates a statistically significant difference from
untreated (control) to treated (dBcAMP) astrocytes while lettering denotes statistically
significant differences within groups using a one-way ANOVA and a Tukey-Kramer post
hoc test (p < 0.05). Reproduced with permission.
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Figure 8. Fractional distribution of tracer into neutral lipid fraction in dBcAMP treated and
untreated astrocytes. The Fractional Distribution of [1-14C]16:0 (upper panel) and [114

C]20:4n-6 (lower panel) for untreated (Control, filled-triangle) and treated (dBcAMP,

unfilled-triangle) astrocytes from 1 to 30 minutes. Values represent means ± standard
deviation (n=5). The asterisk indicates a statistically significant difference from untreated
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(control) to treated (dBcAMP) astrocytes while lettering denotes statistically significant
differences within groups using a one-way ANOVA and a Tukey-Kramer post hoc test (p
< 0.05). Reproduced with permission.

Figure 9. Tracer esterification into individual neutral lipids in dBcAMP treated and
untreated astrocytes. The extent of esterification of [1-14C]16:0 (upper panel) and [136

14

C]20:4n-6 (lower panel) for untreated (Control, filled) and treated (dBcAMP, unfilled)

astrocytes from 30 minutes. Values represent means ± standard deviation (n=5). The
asterisk indicates a statistically significant difference from untreated (control) astrocytes
using Student’s t-test (p < 0.05). Reproduced with permission.

Neutral lipid fractions were differentially altered by dBcAMP treatment

Although differences between groups in esterification of tracers into the neutral
lipid pool was limited, we separated the neutral lipid fraction into individual neutral lipid
classes to determine if dBcAMP treatment had an effect on targeting the tracers to
individual neutral lipid classes. Unlike [1-14C]20:4n-6, targeting of [1-14C]16:0 for
esterification into neutral lipids was significantly increased in diacylglycerol (DAG) (Fig.
9). Both tracers however, had a similar reduction of esterification into CE (Fig. 9) in
dBcAMP treated astrocytes. Overall, treatment enhanced [1-14C]16:0 targeting to
neutral lipids to a greater extent than for [1-14C]20:4n-6. Interestingly, the amount of [114

C]16:0 found in the FFA pool was greater than that of [1-14C]20:4n-6 in non-treated

cultures, suggesting a slower overall rate of [1-14C]16:0 esterification as compared to [114

C]20:4n-6 in non-treated cultures. However, after dBcAMP treatment, esterification of

[1-14C]16:0 free fatty acids was decreased to a similar level as [1-14C]20:4n-6 tracer
(Fig. 9). Both tracers had a limited degree of carbon recycling as noted by the limited
radioactivity in cholesterol (Fig. 9).
mRNA expression of key enzymes associated with Acyl-CoA metabolism is
modulated by dBcAMP

Quantitative real-time PCR was used to evaluate the expression of Acsl-1, -3, -4,
-5, and -6 versions 1-4, which activate fatty acids for metabolism by addition of a CoA to
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the carboxylic acid of the fatty acid. We also evaluated gene expression of Acyl-CoA
thioesterase (Acot7), which hydrolyzes acyl-CoA esters to their non-esterified FFA and
CoASH. In addition, because Snca facilitates Acsl activity toward [1-14C]20:4n-6
(Golovko et al. 2005) and its expression impacts astrocyte fatty acid uptake (Castagnet
et al. 2005), we determined Snca expression. In dBcAMP treated astrocytes there was
a significant 4.8-fold increase in gene-expression of Acsl3 (Fig. 10B) and a significant
1.3-fold increase in Acsl4 (Fig. 10A) gene expression. Both Acsl3 and Acsl4 prefer
20:4n-6 as a substrate (Van Horn et al. 2005; Kang et al. 1997). This increase in gene
expression is consistent with increased uptake and trafficking of [1-14C]20:4n-6 in
dBcAMP treated astrocytes. Acsl3 and -6 are the predominant isoforms found in mouse
brain, there were also minor, but significant changes in expression of Acsl6_v1 and 6_v3
between groups (Fig. 11). Acsl5, which predominately prefers 16:0 as a substrate, was
reduced by 43% (Fig. 11), although 16:0 uptake was unchanged and esterification was
increased suggesting the substantial increase in Acsl3 expression has more of an effect
on 16:0 regardless of substrate preference. Acsl6_v1 was reduced by 25%, while
Acsl6_v3 was increased 1.2-fold in dBcAMP treated astrocytes. Acot7 gene-expression
was reduced by 23% (Fig. 10A), consistent with decreased presence of tracer found in
FFA pools. Because FABP can affect fatty acid uptake and trafficking, we examined the
impact of dBcAMP treatment on astrocytes expression of Fabp3, -5, and -7. Expression
of Fabp7, the major FABP in astrocytes, was reduced 45%, while Fabp5 expression was
reduced 24%, but it is expressed 60-fold less in astrocytes than Fabp7 (Fig. 12). The
expression of Fabp3 was unchanged, and it is expressed nearly 200-fold less than
Fabp7 in astrocytes. This suggests that changes in Fabp do not account for the
increased uptake of 20:4n-6 or the increased esterification of 20:4n-6 or 16:0 into
phospholipids. Interestingly, Snca gene expression was also reduced by 47% in
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dBcAMP treated astrocytes (Fig. 13). Collectively, these results demonstrate that
dBcAMP increased expression of Acsl3, Acsl4, and Acsl6v_3 while Acsl5, Acsl6_v1, and
Acot7 were reduced. These changes in Acsl expression is consistent with the changes
observed in fatty acid uptake and trafficking.
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Figure 10. Effect of dBcAMP treatment on expression of Acsl1, -4, -5 and Acot7 (A) and
Acsl3 (B) in astrocytes. RNA was extracted, cDNA was synthesized, and qRT-PCR
used to determine mRNA expression levels. Values represent means ± standard
deviation for untreated (Control, filled) and treated (dBcAMP, unfilled) astrocytes. The
asterisk indicates a statistically significant difference from untreated (control) astrocytes
using Student’s t-test (p < 0.05). Reproduced with permission.
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Figure 11. Effect of dBcAMP treatment on expression of Acsl6 versions 1-4 in
astrocytes. RNA was extracted, cDNA was synthesized, and qRT-PCR used to
determine mRNA expression levels. Values represent means ± standard deviation for
untreated (Control, filled) and treated (dBcAMP, unfilled) astrocytes. The asterisk
indicates a statistically significant difference from untreated (control) astrocytes using
Student’s t-test (p < 0.05). Reproduced with permission.
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Figure 12. Effect of dBcAMP treatment on expression of Fabp3, -5, and -7 in astrocytes.
RNA was extracted, cDNA was synthesized, and qRT-PCR used to determine mRNA
expression levels. Values represent means ± standard deviation for untreated (Control,
filled) and treated (dBcAMP, unfilled) astrocytes. The asterisk indicates a statistically
significant difference from untreated (control) astrocytes using Student’s t-test (p < 0.05).
Reproduced with permission.
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Figure 13. Effect of dBcAMP treatment on expression of Snca in astrocytes. RNA was
extracted, cDNA was synthesized, and qRT-PCR used to determine mRNA expression
levels. Values represent means ± standard deviation for untreated (Control, filled) and
treated (dBcAMP, unfilled) astrocytes. The asterisk indicates a statistically significant
difference from untreated (control) astrocytes using Student’s t-test (p < 0.05).
Reproduced with permission.
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DISCUSSION

Astrocytes are highly versatile support cells in the CNS. Protoplasmic astrocytes
send out end-feet that establish connections between neurons, endothelial cells
comprising the blood-brain barrier, and glial cells. These interactions are vital in the
homeostatic functions of the brain, particularly having an active role in neurotransmitter
uptake and degradation, glucose uptake and storage, and fatty acid synthesis and
export via apolipoproteins. Furthermore, they play a role in neuronal electric excitability
and synaptic transmission via signal transduction by induced calcium release. After
injury however, alterations in astrocytic morphology and functional state occur as a result
of gliosis. This phenotypic shift to a reactive astrocyte is expected to have a distinct and
active role during neurodegeneration and CNS remodeling. In our model, astrocytes
treated with dBcAMP are found to shift from normal astrocytes into large, stellate,
multiprocessed cells with an enlarged nuclear size consistent with reactive astrocytes.
Astrocytes control cerebral blood flow (Koehler et al. 2009) and are vital in 20:4n6 metabolism. Radiolabeling studies in dBcAMP treated astrocytes show increased
elongation and desaturation of, linoleic acid (18:2n-6) to 20:4n-6, demonstrating that
astrocytes are fully capable of producing 20:4n-6 (Williard et al. 2002). In C6 glioma
cells, dBcAMP treatment enhances 18:2n-6 uptake 1.8-fold and results in a
corresponding increase in 18:2n-6 elongation and desaturation to 20:4n-6 (Robert et al.
1983). Furthermore, co-culturing endothelial cells (Bernoud et al. 1998) or neurons
(Moore et al. 1991) with astrocytes result in a dramatic increase in 20:4n-6 formation
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from 18:2n-6 in these cells. Interestingly, astrocytes cultured alone with 18:2n-6
will release less 20:4n-6 into the medium then when co-cultured with endothelial cells
(Bernoud et al. 1998). This suggests that astrocytes actively sense their surrounding
fatty acid levels and will release 20:4n-6 as needed. Herein, we demonstrate that a
phenotypic shift towards reactive-like astrocytes elicited by dBcAMP treatment
selectively increased the uptake of both 20:4n-6 and enhanced esterification of 20:4n-6
and 16:0 into phospholipids. In addition, incorporation of 20:4n-6 and 16:0 into EtnGpl
was increased ~4-fold suggesting dBcAMP treatment has a selective effect on EtnGpl
metabolism. Overall, dBcAMP administration results in a fatty acid specific increase in
total uptake and a general increase in lipid metabolism.
A critical driving force for fatty acid uptake is the activation of fatty acids by Acsl
to form the acyl-CoA that is then esterified into phospholipids. The rapid incorporation of
fatty acids into phospholipids in dBcAMP treated astrocytes is consistent with dBcAMP
treatment (1 day) increasing total phospholipid levels by 20% (Murphy et al. 1997).
Although we did not measure phospholipid mass herein, our results indicate that
dBcAMP treatment of astrocytes results in increased uptake into the cells (Fig. 1) and
increased targeting of 20:4n-6 to the phospholipid fraction (Fig. 2,3,8). To delineate the
contribution of long chain acyl-CoA synthetases in this observed increase in dBcAMP
astrocytes, we determined mRNA expression of these key lipid enzymes. There are five
long chain acyl-CoA synthetase isoforms in humans and rodents (de Jong et al. 2007;
Watkins et al. 2007). These isoforms differ in their substrate preferences, regulation,
enzyme kinetics, alternative splicing and location. Of these 5 isoforms, Acsl-3 and-6 are
prominently found in the brain (Fujino et al. 1996; Cao et al. 2000; Kee et al. 2003; Van
Horn et al. 2005; Mashek et al. 2006). Acsl-6 is alternatively spliced into four variants
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Acsl6_v1-4 in mouse (Kee et al. 2003; Lee et al. 2005a) and two variants Acsl6_v1 and
-2 in rats (Van Horn et al. 2005). Although fatty acid binding affinity has not been shown
in mouse, Van Horn et. al. demonstrated that rat Acsl6 splice variant 1 prefers linoleic
and alpha-linolenic acids, precursors for 20:4n-6 and docosahexaenoic acid (22:6n-3) ,
respectively, while Acsl6 variant 2 preferentially binds 22:6n-3. This difference in splice
variant affinity demonstrates an important link between Acsl levels and a role in
selectively enhancing fatty acid uptake and metabolism.
This supposition is supported by Acsl isoforms being capable of altering the
synthesis, oxidation of cellular lipids (Muoio et al. 2000; Igal and Coleman 1996; Igal et
al. 1997), and acyl-CoA trafficking to specific metabolic pools (Coleman et al. 2002).
Interestingly, Acsl4 has a high affinity for 20:4n-6 in both mouse and rat (Kang et al.
1997; Van Horn et al. 2005), which has been suggested to play a critical role in
phospholipid reacylation (Muoio et al. 2000; Igal et al. 1997). Our results show dBcAMP
treated astrocytes had increased 20:4n-6 esterification into phospholipids, specifically
ChoGpl, PtdSer, PtdIns, and EtnGpl (Fig. 5), accompanied by a 1.3-fold increase in
Acsl4 expression (Fig. 10A), suggesting that Acsl4 is the major driver in 20:4n-6 uptake.
Notably, a limited degree of tracer was found in neutral lipids, suggesting that the
increased 20:4n-6 taken up was mainly targeted specifically to phospholipid formation
(Fig. 7,8,9).
We also observed minor changes in Acsl6 variant expression. In PC12 cells,
Acsl6 level increases total cellular phospholipids but only marginally increases 20:4n-6
uptake (Marszalek et al. 2005). We observed only relatively small, but significant
changes, in Acsl6_v1 and Acsl6_v3 expression (Fig. 11). Furthermore, Acsl6 have
varying affinities for polyunsaturated fatty acids (Van Horn et al. 2005) and when
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knocked down in mouse brain reduces 20:4n-6-CoA formation (Kee et al. 2003),
suggesting they may play a role in trafficking of 20:4n-6 into specific lipid classes.
The treated astrocytes did not have increased uptake of 16:0 (Fig. 1), but did
exhibit increased mass of [1-14C]16:0 targeted to phospholipids (Fig. 4) due to increased
FFA esterification after dBcAMP treatment (Fig. 9). Similar to Acsl4, Acsl3 is also highly
expressed in brain (Van Horn et al. 2005) and is inhibited by Triacin C (Lewin et al.
2001), a competitive inhibitor of several Acsl. Triacin C inhibition of Acsl3 does not alter
fatty acid oxidation, but reduces triacylglycerol synthesis (Muoio et al. 2000). The
endoplasmic reticulum localization of Acsl3 (Poppelreuther et al. 2012) suggests it has a
role in lipid reacylation. Because Acsl3 expression is significantly increased (Fig. 10B) in
dBcAMP treated astrocytes we believe it plays a role in enhanced esterification of both
16:0 and 20:4n-6 into phospholipid pools. Interestingly, Acsl3 increases uptake of both
18:1 (oleic acid) and 20:4n-6 in COS cells (Poppelreuther et al. 2012), which is
consistent with our observations. This coupled with varying kinetic properties based
upon fatty acid, including a lower Vmax of Acsl3 and -4 for 16:0 (Van Horn et al. 2005),
may also account for the lack of increased 16:0 uptake into dBcAMP treated astrocytes.
While Acsl5, which prefers saturated fatty acids as a substrate (Van Horn et al. 2005),
was reduced 43%, we did not see a corresponding reduction in 16:0 uptake. This
suggests that any influence that this change in Acsl5 expression may have had on 16:0
uptake was masked by the significant increase in Acsl3 expression.
FABP3 selectively facilitates brain 20:4n-6 uptake and trafficking (Murphy et al.
2005). Because 20:4n-6 uptake is increased in dBcAMP treated astrocytes, alterations
in expression of Fabp3 could be a potential mechanism for the increase in dBcAMPtreated astrocyte 20:4n-6 uptake. However, Fabp3 expression was unchanged and was
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expressed at negligible levels in dBcAMP treated astrocytes (Fig. 12) as compared to
Fabp7. This suggests that the increased expression of Acsl3 and Acsl4 had a major role
in the increased 20:4n-6 uptake and esterification. This supposition is consistent with
the decreased expression of Fabp7 and Fabp5 observed in the dBcAMP treated
astrocytes, as a reduction in the expression of these FABP is not consistent with an
increase in 20:4n-6 uptake. Although FABP7 may significantly impact 22:6n-3 uptake
and trafficking, it poorly binds to 16:0 (Balendiran et al. 2000), further supporting our
hypothesis that increased Acsl activity differentially impact fatty acid uptake in dBcAMP
treated astrocytes.
In astrocytes, Snca ablation reduces 16:0 and 20:4n-6 uptake and reduced
targeting to phospholipids pools which enhance trafficking to neutral lipid pools
(Castagnet et al. 2005). Herein, we report a significant decrease in Snca expression
after dBcAMP treatment but with an increase in 20:4n-6 uptake suggesting that
enhanced Acsl expression may have a more robust effect on fatty acid metabolism than
Snca. This is important because Snca has a major role in brain 20:4n-6 metabolism
(Golovko et al. 2006a). Therefore, further study on the effect of dBcAMP treatment on
the mRNA expression and protein levels of Snca are required to determine its
association with changes in uptake and incorporation.
In summary, dBcAMP treatment of astrocytes impacted both 16:0 and 20:4n-6
astrocytic metabolism. However, this treatment increased cellular fatty acid uptake of
only 20:4n-6, suggesting that during dBcAMP treatment, astrocytes had an increased
need for 20:4n-6, which is supported by the increased initial rate of incorporation into
phospholipids. Because 16:0 and 20:4n-6 were highly esterified with dBcAMP
treatment, we hypothesize there is a metabolic FA-CoA pool targeted specifically for
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phospholipids by dBcAMP treatment via increased acyl-CoA synthetase expression,
especially Acsl3 and -4, and resulted in an overall increase in phospholipid
incorporation. These results are important because they are the first to demonstrate the
preferential increase in 20:4n-6 uptake and increased esterification of both 20:4n-6 and
16:0 coincide with increased expression of acyl-CoA synthetases in a model of reactive
astrocytes.
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CHAPTER III
INTRODUCTION
Microglia, Snca, and Inflammation

Microglia are known as the resident immune cell of the central nervous system
that play a vital role in immune response and maintenance in the brain (Kabba et al.
2017; Kim and de Vellis 2005). Microglia reactivity and activation are suggested as an
early defense mechanism for the CNS following pathological events (Subramaniam and
Federoff 2017; Kreutzberg 1996; von Bernhardi et al. 2015). During activation microglia
show a phenotypic shift, proliferation, chemotaxis towards areas of damage or infection,
and release potent mediators such as PGE2 or TNFα (Park et al. 2008; Fischer and
Reichmann 2001; Babcock et al. 2013; Fan et al. 2017; Levi et al. 1998). Microglia are
vital in phagocytosis of apoptotic cells and removal of debris as well as bacteria from the
brain (Kaur et al. 2004; Hughes et al. 2010; Ulvestad et al. 1994; Fincher et al. 1996).
Interestingly, depending on phenotype microglia have cytotoxic or neuroprotective
effects (Franco and Fernández-Suárez 2015).
Microglia express vital components of the endocannabinoid (eCB) system
including receptors, ligands, and metabolic enzymes (Mecha et al. 2016). The
endocannabinoid receptor 1 (CB1r) was first cloned in 1990 (Matsuda et al. 1990) and is
found throughout the nervous system (Herkenham et al. 1990), immune system,
adipose, liver, muscle, kidney, reproductive system, and lungs (Pagotto et al. 2006a;
Pagotto et al. 2006b). This system plays a vital role in analgesia, synaptic plasticity
(learning and memory), appetite, immune function and several other physiological
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events (Hohmann et al. 1995; Di Marzo and Deutsch 1998; Cravatt et al. 2001;
Brenowitz and Regehr 2005; Kishimoto 2006; Pagotto et al. 2006a). The CB1r belong to
the GPCR family (Mukhopadhyay and Howlett 2001; Herkenham et al. 1990) and are the
most highly expressed GPCR in the brain (Devane et al. 1988; Herkenham et al. 1990).
CB2r, which shares 44% homology, was first cloned several years later in 1993 (Munro
et al. 1993) and is more prevalent in immune cells (Galiègue et al. 1995). CB1 and -2
receptors are highly expressed in both murine and human macrophages (Carlisle et al.
2002; Chiurchiù et al. 2015). The CB2r is regulated during pathological insult and CB2r
stimulation inhibits microglia reactivity and promotes a neuroprotective phenotype. eCB
are bioactive lipids which play a role in lipid signal transduction events and increased
levels coincide with or shortly follow immune function and eCB metabolism enzymes are
modulated in response to inflammatory stimuli.
There are two prominent arachidonic acid containing eCB N-arachidonyl
ethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). In this section we will be
focusing on 2-AG as that is the most prevalent endogenous CNS agonist of CB2r (Di
Marzo et al. 1998; Bisogno et al. 1999). In general, 2-AG is synthesized from membrane
phospholipids and released on demand in response to stimuli (Di Marzo and Deutsch
1998). Some data suggests that at least part of the eCB pool may be stored before
release (Alger and Kim 2011), suggesting that eCB may be accumulated and trafficked
before release. However, the notion of preformed 2-AG pools is still debated
(Hashimotodani et al. 2013).
2-AG biosynthesis follows one of two pathways. One pathway is the result of
either α- or β-diacylglycerol lipase, a calcium-sensitive sn-1 selective lipase that cleaves
the sn-1 position of sn-2-arachidonate containing diacylglycerol. The sn-2-arachidonate
containing diacylglycerol is derived primarily from hydrolysis of membrane phospholipids
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by phospholipase C, (PLC) (Bisogno et al. 2003). The other less prevalent pathway is
the hydrolysis of arachidonic acid containing lysophosphatidic acid by a phosphatase
(Nakane et al. 2002; Higgs and Glomset 1994). This is important because Snca
increases PLC activation which drives the generation of DAG (Narayanan et al. 2005).
To inactivate 2-AG, two steps are required. First 2-AG must be taken up into a cell
followed by hydrolysis. It can be hydrolyzed by fatty acid amide hydrolase or in most
cases (85%), monoacylglycerol lipase or cleaved by α/β serine hydrolase domaincontaining proteins 6 & 12 (Blankman et al. 2007). 2-AG may also be metabolized into
highly bioactive signaling molecules as it is a substrate for COX (Straiker et al. 2011;
Richie-Jannetta et al. 2010), LOX (Kozak et al. 2002; Kozak and Marnett 2002), and
cytochrome P450 and phosphorylation to produce lysophosphatidic acid (Bektas et al.
2005). Without a doubt eCB play a major role in the homeostasis of the nervous system
and pharmacologically increasing levels of eCB shows some resistance to
neurodegenerative disease.
The presence of reactive microglia are a hallmark of Parkinson’s disease
(Subramaniam and Federoff 2017; Kim and de Vellis 2005). With increased Parkinson’s
progression there is a consistent increase in CD68 stained microglia (Croisier et al.
2005). This reactivity is widespread and not limited to the substantia nigra where the
death of dopaminergic neurons is the result of Parkinsonian pathology. In MPTPinduced Parkinson’s disease there is a substantial shift of microglia to a reactive
phenotype and this activation is maintained for several years (Barcia et al. 2004;
McGeer et al. 2003). This suggests that microglial activation and maintenance of its
reactive phenotype is important in disease progression.
Lipopolysaccharide (LPS) and interlukin-1β increase α and β-Snca mRNA
expression and protein levels in human astrocytes and macrophages suggesting a role
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in inflammation (Tanji et al. 2001; Tanji et al. 2002). Interestingly, stimulation by purified
Snca protein is able to induce a phenotypic shift to a reactive state and induces
increased cytokine secretion in microglia (Zhang et al. 2005; Klegeris et al. 2008).
Similarly, microglia and macrophages become activated by stimulation of either
monomeric or fibrillary aggregates of Snca (Zhang et al. 2005; Wilms et al. 2009; Lee et
al. 2009). Our lab has previously hypothesized that either extra or intra cellular Snca
modulates microglia activity (Austin et al. 2011; Rojanathammanee et al. 2011; Floden et
al. 2005). To further support the idea that Snca plays an important role in
proinflammatory lipid-dependent signaling events we determined if Snca expression has
an impact on 2-AG levels following LPS treatment.
Lipid mediated signaling pathways are important in microglia activation and Snca
expression modulates microglia activation state. PLD2 is required for activation of
macrophages in response to LPS and TNFα. We and others have determined Snca
tonically inhibits PLD and therefore Snca plays a role in PLD mediated microglia
activation (Austin et al. 2011; Jenco et al. 1998; Ahn et al. 2008; Payton et al. 2004;
Outeiro and Lindquist 2003). Increased expression of Snca has been found following
stimulation (Milner and Campbell 2003) and microglia of Snca gene-ablated mice are
phenotypically different from wildtype (Austin et al. 2006) suggesting Snca plays a
pivotal role in activation. Microglia from gene-ablated mice demonstrate a hyperreactive, ramified, vacuolar morphology with an increased cytokine secretory phenotype
compared to wild type and exacerbated reactive phenotype following LPS treatment, but
with a significantly decreased phagocytic ability (Austin et al. 2006). Microglia activation
markers CD68, β1 integrin and α tubulin are increased in Snca deficient microglia and
are further exacerbated with LPS treatment (Austin et al. 2006). Snca deficient microglia
release increased levels of proinflammatory cytokines TNFα and IL-6 (Austin et al. 2006;
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Austin et al. 2011). In BV-2 cells over-expressing wild type and mutant forms of Snca,
there is no change in PLD1/2, PLA2, or COX-1 protein levels, but COX-2 protein levels
are significantly increased (Rojanathammanee et al. 2011). This suggests that Snca
selectively regulates protein expression and that the effect of Snca on PLD activity is not
a result of decreased protein levels. BV-2 cells expressing Snca and its mutants
showed a similar reduction as primary Snca gene-ablated microglia in phagocytic ability
and interestingly BV-2 cells over expressing Snca are not neurotoxic to neurons
(Rojanathammanee et al. 2011). These data suggest a fundamental role for intercellular
Snca in regulation of microglia phenotypic shift and Snca’s important role in the
inflammatory response.
Herein, we determine if Snca plays a role in 2-AG release from whole brain and
microglia following LPS stimulation. We utilized a Snca gene-ablated and Snca knock-in
mouse model and primary postnatal microglia from these wild type and Snca geneablated mice. Snca deficient mice have elevated basal levels of 2-AG that was
exacerbated by LPS stimulation. Snca knock-in mice had variable 2-AG levels that were
within the wildtype and Snca deficient mice levels. However, Snca expression was not
changed during the 3 hour LPS stimulation in wildtype mice. Inversely in wild type
primary microglia there was a significant reduction of 2-AG following LPS stimulation
after 12 hours of stimulation. This reduction remains prevalent at 18 hours and was
accompanied by a reduction in Snca expression. When expressed as % control
enhanced eicosanoid production follows this same timeline. Interestingly, Snca deficient
microglia show a delayed reduction of 2-AG, requiring 24 hours of LPS treatment to be
significantly reduced. However, their basal eicosanoid production is exacerbated as
compared to wildtype. This data suggests that Snca plays an important role in early 2-
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AG lipid mediated signaling which may have downstream effects on microglia phenotype
and phagocytic ability.
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MATERIALS AND METHODS
Mice

This study was conducted in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals and under an animal protocol
approved by the University of North Dakota IACUC (Protocol 0708-1c). The wild type
mice used for the protocol were the 129/SvEv strain, Snca gene-ablated mice generated
by gene-targeted deletion of Snca, or Snca knock-in mutant (A30P and A53T) or human
(hSnca) on the 129/SvEv background (Cabin et al. 2002). Male mice were age matched
~10 months old and were given standard laboratory chow and water ad libitum.
LPS treatment and tissue collection

Previously published data showed no difference in blood brain barrier
permeability between single does and divided doses of LPS (Jangula and Murphy 2013),
we used a single dose of lipopolysaccharide (LPS) derived from E. coli 055:B5 J (Sigma
cat# L2880) dissolved in phosphate buffered saline (0.25 mg/mL). Mice were injected
with LPS (1 mg/kg) intraperitoneally (i.p.). Whole brain was removed, flash frozen in
liquid nitrogen, and then pulverized into a homogeneous powder under liquid nitrogen
conditions.
Cells

Mouse glia were isolated from brains of 1 day old 129/SvEv mice under an
approved protocol by the University of North Dakota (Grand Forks, ND) Animal Care and
Use Committee (UND protocol #1106-1C). To obtain astrocytes, cortices were triturated
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in Dulbecco’s modified Eagle’s medium (DMEM) to separate cells, filtered
through 80 µm Nylon mesh, and resuspended in DMEM containing 10% fetal bovine
serum (FBS). Astrocytes were cultured in DMEM containing 10% FBS, 3.7 g/L
bicarbonate, 2 mM glutamine, 100 µg/mL penicillin/streptomycin, and 5 mM HEPES at
pH 7.4 in a water jacketed incubator at 37°C in 5% CO2 atmosphere. Astrocytes were
expanded by subculturing on T-75 flasks (4:1) by loosening the adherent cells with
0.25% trypsin. The third passage (3:1) was plated on 100 mm polystyrene cell culture
plates prior to treatment with dBcAMP.
To obtain microglia, cortices were collected into dissection buffer containing 1
mM EDTA, 1 mM EGTA, 1 mg/mL glucose in phosphate buffered saline and
mechanically separated with forceps. Two volumes of 0.25% trypsin was added and the
tissue was incubated for 15 mins. Following incubation trypsin was inhibited with the
addition of microglia media containing DMEM:Hams F12 (1:1) medium 10% FBS, 5%
Horse serum, 3.7 g/L bicarbonate, 2 mM glutamine, 100 µg/mL penicillin/streptomycin,
and 5 mM HEPES at pH 7.4. Cells were triturated to break up tissue and filtered through
80 µm Nylon mesh and resuspend in microglia medium in T-75 flasks. Medium was
changed after 48 hours and then again after one week. Microglia were collected
between days 10 -14 by shaking flasks for 45 mins at 200 rpm on an orbital shaker and
plated on 6-well polystyrene cell culture plates in half conditioned media and half new
media at ~250,000 cells per well. Microglia are allowed to reattach and equilibrate for 24
h before LPS treatment (50 ng/mL) in microglia medium.
Mass Spectrometry Lipid Extraction

To homogenized brain tissue samples, analytes were extracted from the tissues
using a two-phase extraction method. Homogenized tissue was added directly to a
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Tenbroeck homogenizer containing 100 ng of 2-arachidonyl glycerol-d5 and 100 pg
prostaglandin E2-d4 standards in 1 mL of saline. To the Tenbroeck homogenizer 1 mL of
acetone was added followed by homogenization of tissue. Once tissue was
homogenized, the extract was removed using a silanized Pasture pipette, saved in a
silanized screw top test tube and then the homogenizer was washed with 1 mL of
acetone and the wash added to the initial extract. Then protein residue was pelleted by
centrifugation at 3,250 x g for 15 min at 4 °C and the supernatant was moved to a new
silanized tube.
For microglia medium, analytes were extracted from the medium using a twophase extraction method. Microglia medium (1 mL) was added directly to a silanized
test tube containing 1 ng of 2-arachidonyl glycerol-d5 and 100 pg prostaglandin E2-d4
standards in 2 mL acetone. After protein removal (brain samples only) 2 mL of hexane
was added to the extract, vortexed, and centrifuged at centrifugation at 3,250 xg for 15
min at 4 °C. The upper phase containing 2-arachidonyl glycerol (2-AG) was transferred
to a new silanized tube for later quantification. The extract was washed two more times
with 2 mL of hexane and the upper phase saved. To the lower phase containing
eicosanoids, 30 µL of 2 M formic acid and 2 mL chloroform containing 0.005% BHT was
added, vortexed and centrifuged. The bottom chloroform phase containing eicosanoids
was removed and placed in a new silanized tube. To the chloroform phase, 200 µL of
methanol was added and the sample was evaporated under N2 (g). The sample was
then transferred to a silanized micro insert using 150 µL of chloroform/methanol (9:1 by
vol.). The tube containing extract was washed with 150 µL of chloroform/methanol (9:1
by vol.) and added to the micro insert. and dried down under N2 (g). The sample was
then redisolved in methanol/water (1:1 by vol.) and proceeded to LC-MS analysis. The
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hexane phase containing 2-arachidonyl glycerol and arachidonyl ethanolamide was
dried down under N2 (g) and 1 mL of acetonitrile was used to resuspend the analytes.
20 µL of the sample was mixed with 20 µL of water in a silanized micro insert and used
for analysis by LC-MS.
Liquid Chromatography-Mass Spectrometry (LC-MS) analysis

The above extracts prepared for analysis of 2-AG, AEA, and eicosanoids were
then analyzed by LC- MS as previously described (Brose et al. 2016; Brose and Golovko
2013). 2-AG was resolved using a Waters ACUITY UPLC HSS T3 column (1.8 µM, 100
Å pore diameter, 2.1 x 150 mm, Waters, Milford, MA) with an ACUITY UPLC HSS T3
precolumn (1.8 µM, 100 Å pore diameter, 2.1 x 150 mm, Waters, Milford, MA) at a
temperature of 55°C. The LC system was configured with a Waters Acuity UPLC pump
and autosampler set at 8°C. The LC eluent was analyzed using a triple quadrupole
mass spectrometer (Xevo TQ-S, Waters) with electrospray ionization operated in
positive ion mode. The capillary voltage was 2.35 kV and the cone voltage was 30V.
The desolvation temperature was 550°C with a source temperature of 150°C. The
desolvation gas flow was 1000 L/hr, the cone gas flow was 150 L/hr, and the nebulizer
gas was at 7.0 Bar. MassLynx V4.1 software (Waters) was used for instrument control,
data acquisition and sample analysis. The 2-AG and eicosanoids were quantified, using
2-AG-d8 and PGE2-d4 as the internal standard, respectively. The analytes were
monitored in multiple reaction monitoring mode using 12 V for collision energy and the
following mass transition for analytes and their internal standards: 2-AG 379.3/287.7 and
2-AG-d8 387.5/294.4, PGE2 351.2/189.5 and PGE2d4 355.2/275.5.
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Quantitative real-time PCR

RNA was extracted from microglia using the Qiagen RNeasy Kit and quantified
on an Epoch spectrophotometer system (BioTek, Winooski, VT, USA). Optical density
was used to verify RNA concentration at 260 nm and genomic DNA contamination by
260/280 nm ratio. Then 100 ng to 1 µg of total RNA was used for first strand synthesis
using the SuperScript III First-Strand Synthesis System primed with random hexamers
(Life Technologies, NY, USA). cDNA was quantified using a Bio Rad CFX96 real-time
PCR detection system using Power SYBR green master mix (Life Technologies, NY,
USA). Primers used for Snca and Sdha are shown in Table 2. Samples were predenatured (95°C for 10 m) then a polymerase-activation program (45 cycles of 95°C for
15 s, 55°C for 30 s, and 72°C for 30 s) was followed by post-annealing at 72°C for 120 s.
Then a melting temperature (Tm) curve program (60-95°C ramp at 0.5°C/s) was used to
identify amplification contaminants. A common threshold of fluorescence was set and
using the absolute standard curve method, the number of cycles (Ct) was used to
determine absolute number of copies of target gene cDNA. Endogenous control
succinate dehydrogenase complex, subunit A, (flavoprotein) Sdha, was used to
normalize target gene copy number found by qRT-PCR, resulting in a ratio of target
gene to endogenous control gene.

Isoform

Forward Primer

Reverse Primer

Sdha

CCTACCCGATCACATACTGTG

AGTTGTCCTCTTCCATGTTCC

Snca

GCCCTTGCCTCTTTCATTG

GTCCTTTCATGAACACATCCATG

Table 2. Primer sequences used for microglia qRT-PCR
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Statistics

Statistical analysis was done using Instat® statistical program (Graphpad, San
Diego, CA). Multiple comparisons were assessed using a one-way ANOVA and a
Tukey-Kramer post hoc test, with p < 0.05 considered to be significant. Where
appropriate (Fig. 6, 9, 10, 11, and 12) Student’s two-tailed t-test was used to determine
significance between treatment groups, with p < 0.05 considered to be significant. Each
time point contains samples from five (n=5) individually treated separate cell cultures.
For analysis of gene-expression, mice n=5 and microglia n=3.
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RESULTS
Microwave irradiation is crucial in determining basal 2-arachidonyl glycerol levels
in mouse brain.

Because 2-AG levels may be impacted by post-mortem delay and because we
have found that microwave irradiation limits changes in lipid release during post-mortem
delay (Murphy 2010), I determined the impact of post-mortem delay on 2-AG levels.
Non-microwave irradiated brains had significantly higher 2-AG levels than microwave
irradiated brains (Figure 14). There was no significant difference in 2-AG levels between
mice expressing different forms of Snca that were not microwave irradiated before
removal of brain that was dependent on the form of Snca expression. However, there
were several differences between microwave irradiated brains. Snca gene-ablated mice
have significantly increased basal 2-AG levels (39.2 ng/gww) compared to wild type
mice (7.5 ng/gww) (Figure 14). Interestingly, the human Snca knock-in mice have some
reduction of 2-AG levels (24.0 ng/gww) when compared to Snca gene-ablated mice
(Figure 14), but hSnca does not fully reduce basal 2-AG levels to wild type
concentrations. There is a similar observation for both A30P (13.1 ng/gww) and A53T
(19.1 ng/gww) mutant Snca knock-in mice having concentrations between the wild type
and Snca gene-ablated mice (Figure 14). This suggests that the addition of human or
mutant Snca restores some function with regards to basal 2-AG levels. Importantly,
there was a significant 240-fold increase in wild type mouse brain 2-AG levels in the
brains of mice not microwave irradiated vs microwave irradiated (Figure 14). Therefore,
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removal of brain from cranial vault without heating the brain in situ prior to removal
results in a substantial significant increase in 2-AG levels.

Figure 14. 2-AG levels in microwaved vs non-microwaved mouse brain. 2-AG levels in

WT, KO, hSnca, A30P, A53T mice microwave irradiation (black) and not-microwave
irradiated (gray). Values represent means ± standard deviation (n=4-6). Lettering
denotes statistically significant differences between groups using a one-way ANOVA and
a Tukey-Kramer post hoc test (p < 0.05).

Snca gene-ablated mice have exacerbated 2-AG levels from LPS treatment.

Because we found a significant difference between basal 2-AG levels we
determined how LPS treatment will affect 2-AG levels differently in mice. We found no
significant difference of basal levels of Snca expression in wildtype mice or after 3 hours
of LPS treatment (Figure 15). Because LPS treatment does not affect Snca level
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expression in wild type mice, this suggests that 2-AG level changes in LPS treated mice
is not a result of differences in Snca expression.

Figure 15. Snca expression in brains of wild type mice treated with LPS. Snca

expression levels in wild type mice following 3 hour LPS (1mg/kg, i.p.) treatment. Values
represent means ± standard deviation (n=5). The asterisk indicates a statistically
significant difference from untreated mice using Student’s t-test (p < 0.05).

We did however, find a significant 1.4-fold increase in 2-AG levels of wild type mice after
3 hour LPS treatment (Figure 16). This significant difference was also found in Snca
gene-ablated mice. However, LPS treatment of Snca gene-ablated mice resulted in a
1.7-fold increase of 2-AG levels. Interestingly, basal 2-AG levels in Snca gene-ablated
mice were significantly increased 1.24-fold over wildtype levels (Figure 16). This
indicates that Snca gene-ablated mice have higher basal levels of 2-AG and that LPS
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treatment causes a significantly higher increase of 2-AG as compared to the increased
observed in wild type mice.

Figure 16. Brain 2-AG levels in wild type and Snca gene-ablated mice basal and treated

with LPS. 2-AG levels in wild type and Snca gene-ablated (KO) mice following 3 hour
PBS (basal) or LPS (1mg/kg, i.p.) treatment. Values represent means ± standard
deviation (n=5). The asterisk indicates a statistically significant difference from groups
using Student’s t-test (p < 0.05).

LPS treatment in immortalized mouse microglia increases 2-AG levels

Because 2-AG is an important signaling molecule in microglia macrophage phenotype
we determined if LPS (50 ng/mL) treatment affects 2-AG and prostaglandin levels. In
BV-2 (C57BL/6 mouse brain microglia immortalized cells) an 18 hour LPS treatment
resulted in a significant 2.8-fold increase in 2-AG levels (Figure 17).

65

Figure 17. 2-AG levels in BV-2 microglia medium treated with LPS. 2-AG levels in BV-2

immortalized mouse microglia following 18 hours of LPS (50 ng/ml) treatment or no
treatment (basal control). Values represent means ± standard deviation (n=5). The
asterisk indicates a statistically significant difference from control using Student’s t-test
(p < 0.05).

After 18 hours of LPS treatment eicosanoid levels were also determined. Prostaglandin
E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α) were significantly
increased while thromboxane B2 (TXB2) and 6-keto prostaglandin F1α (6-ketoPGF1α)
were unchanged (Figure 18). The massive increase in PGE2 and PGD2, 10-fold and 168fold, respectively, suggests that there is a substantial microglia reaction phenotype as
expected with LPS treatment.
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Figure 18. Prostaglandin levels in BV-2 microglia medium treated with LPS.

Prostaglandin levels in medium of BV-2 immortalized mouse microglia following 18
hours of LPS (50 ng/ml) treatment or no treatment (control). Values represent means ±
standard deviation (n=5). The asterisk indicates a statistically significant difference from
control using Student’s t-test (p < 0.05).

BV-2 cells were very effective at showing a significant reaction to LPS however, we and
others (Kim et al. 2009) have found that BV-2 cells do not express Snca at a level high
enough to quantify by RT-qPCR or protein levels quantifiable by Western blotting.
Because of the lack of Snca expression another model would have to be utilized to
determine if Snca expression affects 2-AG levels.
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Primary Snca gene-ablated microglia have reduced basal 2-AG levels.

Because BV-2 cells did not express Snca, we chose to use a model that naturally
contains Snca instead of transfecting BV-2 cells which may negatively perturb the BV-2
system. Therefore, primary wild type and Snca gene-ablated (KO) microglia were used.
Unlike mouse brain, primary gene-ablated microglia had a 59% reduction in basal levels
of 2-AG released in the medium (Figure 19). This suggests that in unstimulated primary
microglia, Snca gene-ablation has a significant effect on 2-AG levels. Our previously
published data determined that Snca gene-ablated microglia have higher basal total
prostaglandin release into the medium partially due to increased phospholipase D2
(PLD2) and cyclooxygenase-2 (COX-2) levels (Austin et al. 2011).

Figure 19. Basal 2-AG levels in medium of wild type and Snca gene-ablated primary

microglia. Values represent means ± standard deviation (n=5). The asterisk indicates a
statistically significant difference from control using Student’s t-test (p < 0.05).
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Primary microglia had reduced 2-AG levels but increased eicosanoid production
after LPS treatment.

Because we are interested in Snca effect on inflammation we treated primary microglia
at several time points with LPS to induce a reactive phenotype. After 6 hours of LPS
treatment there was no significant difference in 2-AG levels in the medium (Figure 20).

Figure 20. 2-AG levels in medium of primary microglia after 6 h of LPS treatment. 2-AG

levels in medium of primary mouse microglia following 6 hours of LPS (50 ng/ml)
treatment or no treatment (basal control). Values represent means ± standard deviation
(n=3).

There was also no significant difference in Snca expression levels after 6 hours of LPS
treatment in wild type microglia (Figure 21). here was however, an 80% decrease in
TXB2 and a significant 2.8-fold increase in PGD2 released into the medium of wild type
microglia (Figure 22). This data suggests that while small changes occured in released
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eicosanoids, 6 hours of LPS treatment does not affect either Snca expression or alter
the amount of 2-AG levels released into the medium, but does impact PGD2 synthesis

Figure 21. Snca expression in primary microglia with 6 h LPS treatment. Snca

expression levels in primary microglia following 6 hour LPS (1mg/kg, i.p.) treatment.
Values represent means ± standard deviation (n=3).
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B continued
Figure 22. Prostaglandin levels in medium of primary microglia treated with LPS 6 h.

Prostaglandin levels in medium of primary mouse microglia following 6 hours of LPS (50
ng/ml) treatment or no treatment (control). Values represent means ± standard deviation
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(n=3). The asterisk indicates a statistically significant difference from control using
Student’s t-test (p < 0.05).

However, after 18 hours of LPS treatment there was a significant 59% reduction in 2-AG
levels in medium of wild type microglia (Figure 23). Concomitantly, there was a
significant albeit small reduction (17%) in Snca expression in wild type microglia (Figure
24).

Figure 23. 2-AG levels in medium of primary microglia after 18 h LPS treatment. 2-AG

levels in medium of primary mouse microglia following 18 hours of LPS (50 ng/ml)
treatment or no treatment (basal control). Values represent means ± standard deviation
(n=3). The asterisk indicates a statistically significant difference from control using
Student’s t-test (p < 0.05).
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Figure 24. Snca expression in primary microglia with 18 h LPS treatment. Snca

expression levels in primary microglia following 18 hour LPS (1mg/kg, i.p.) treatment.
Values represent means ± standard deviation (n=3). The asterisk indicates a statistically
significant difference from basal control using Student’s t-test (p < 0.05).

After 18 hours of LPS treatment there was a large increase in several eicosanoids in the
medium of primary wild type microglia similar to those found in BV-2 cells treated for 18
hours with LPS. PGD2 was increased 138-fold, PGF2α was increased 23-fold, TXB2 was
increased 7.8-fold, and PGE2 was increased 173-fold in medium of LPS treated primary
microglia (Figure 25).
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B continued
Figure 25. Prostaglandin levels in medium of primary microglia treated with LPS 18 h.

Prostaglandin levels in medium of primary mouse microglia following 18 hours of LPS
(50 ng/ml) treatment or no treatment (control). Values represent means ± standard
deviation (n=3). The asterisk indicates a statistically significant difference from control
using Student’s t-test (p < 0.05).
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2-AG levels and Snca expression are reduced at the same time point after LPS
treatment.

To determine if Snca expression and 2-AG levels change over time of LPS treatment,
we examined Snca expression at several different time points and expressed data as
percent control. We found that after 12 hours of treatment there was a significant
reduction in released 2-AG levels vs control (Figure 26). This significant reduction was
similar to what we found in Snca gene expression after 12 hours of LPS treatment
(Figure 27).

Figure 26. 2-AG levels in medium of primary microglia time response following LPS

treatment. 2-AG levels expressed as % control in medium of primary mouse microglia
following 6, 12, or 18 hours of LPS (50 ng/ml) treatment. Values represent means ±
standard deviation (n=3). The asterisk indicates a statistically significant difference from
control using Student’s t-test (p < 0.05).
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Similarly, Snca gene expression was reduced after 12 hours of LPS treatment in wild
type primary microglia (Figure 27). These data suggests that both 2-AG released into
medium and Snca expression is reduced concomitantly in primary microglia after 12
hours of LPS treatment.

Figure 27. Snca expression in primary microglia time response following LPS treatment.

Snca expression levels expressed as % control in primary microglia following 6, 12, or
18 hour of LPS (1mg/kg, i.p.) treatment. Values represent means ± standard deviation
(n=3). The asterisk indicates a statistically significant difference from basal control using
Student’s t-test (p < 0.05).

Primary Snca gene-ablated microglia have reduced 2-AG levels but increased
eicosanoid production after LPS treatment.

Because Snca expression was significantly reduced concomitantly with 2-AG levels in
wild type mice following LPS treatment it suggests that Snca expression may impact 276

AG and eicosanoid synthesis sin microglia. To test this hypothesis, we treated Snca
gene-ablated primary microglia with LPS. A significant reduction of 2-AG occurred at 24
hours of LPS treatment in microglia from gene-ablated mice (Figure 28), whereas for
wild type microglia, this reduction occurred at 12 hours (Figure 26).

Figure 28. 2-AG levels in medium of Snca gene-ablated primary microglia after 18 or 24

h of LPS treatment. 2-AG levels in medium of primary mouse microglia following 18 or
24 hours of LPS (50 ng/ml) treatment or no treatment (basal control). Values represent
means ± standard deviation (n=3). The asterisk indicates a statistically significant
difference from control using Student’s t-test (p < 0.05).

Interestingly, at 24 hours of LPS treatment there were significant differences in
eicosanoids however, several were differentially modulated. PGE2, PGD2 and TXB2
were increased following LPS treatment in a manner similar to wild type microglia
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(Figure 29). However, PGF2α was significantly reduced in Snca gene-ablated microglia,
but in wild type microglia there was a significant increase after 18 hours of LPS
treatment. 6-ketoPGF1α was significantly reduced in Snca gene-ablated mice, but not in
wild type mice.
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Figure 29. Prostaglandin levels in medium of primary Snca gene-ablated microglia

treated with of LPS 24 h. Prostaglandin levels in medium of primary mouse microglia
following 24 hours of LPS (50 ng/ml) treatment or no treatment (control). Values
represent means ± standard deviation (n=3). The asterisk indicates a statistically
significant difference from control using Student’s t-test (p < 0.05).

To determine the inflammatory state of the microglia we looked at combined eicosanoid
levels in medium of wild type basal (Ctr), wild type LPS treated (WT), and Snca geneablated LPS treated (KO) primary microglia. Interestingly, there was not a significant
change in WT microglia combined eicosanoid release between 6 and 12 hours of LPS
treatment which was unexpected (Figure 30). There was however, a drastic increase in
combined eicosanoids between 12 and 18 hours of LPS treatment in wild type microglia.
Snca gene-ablated microglia with LPS treatment had exacerbated combined eicosanoid
levels as compared to wild type, suggesting a more inflammatory phenotype. These
data together suggests a role of Snca in modulating both 2-AG levels and eicosanoids
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as a result of LPS treatment and subsequent inflammatory phenotype of microglia. This
conclusion is supported by the correlation between a decrease in Snca expression in
wild type microglia and an increase in total prostaglandin production.

Figure 30. Combined prostaglandin level time response in medium of wild type and

Snca gene-ablated primary microglia treated with LPS. Total prostaglandin time
response in medium of wild type and Snca gene-ablated primary mouse microglia
following LPS (50 ng/ml) treatment or no treatment (control). Values represent means ±
standard deviation (n=3). Lettering change denotes statistically significant differences
between groups using a one-way ANOVA and a Tukey-Kramer post hoc test (p < 0.05).
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DISCUSSION

I determined if alterations in Snca expression resulted in changes in 2-AG
release during LPS treatment, examining this role in whole brain and in microglia
isolated from the brains of wild type and Snca deficient mice. I have focused on
identifying changes that result from the absence of Snca to determine if its normal
physiologic role is as a molecular switch in microglia, shifting microglia biochemical
phenotype. The role of Snca in lipid mediated signal transduction is well established and
the results presented here suggest that Snca has a role or at least a concomitant gene
expression reduction in microglia with increasing time of LPS stimulation. In wild type
microglia there was a concomitant reduction in 2-AG release into the medium following
LPS treatment in a time-dependent manner (Figures 26, 27). Furthermore, Snca
deficient microglia showed a similar reduction in 2-AG release but revealed a delayed
response to LPS stimulation. Interestingly, Snca expression in whole brain was not
changed following 3 hour stimulation with LPS but Snca deficient mice had increased
basal 2-AG synthesis that was further increased by LPS treatment.
Snca has a crucial role in brain lipid metabolism and significantly alters the
brains inflammatory state (Golovko et al. 2005; Golovko et al. 2006a; Perrin et al. 2000;
Trexler and Rhoades 2009; Bodner et al. 2010; Ramakrishnan et al. 2006; BarcelóCoblijn et al. 2007; Murphy et al. 2008; Golovko et al. 2006b). The role of Snca in
arachidonate recycling (Golovko et al. 2006a) and the increase in PG synthesis following
ischemia (Golovko and Murphy 2008) is consistent with the decreased 2-AG level and
increased eicosanoid, especially PGE2 and PGD2, synthesis observed in microglia
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following LPS treatment. While, others have shown that overexpression of Snca
is toxic to neurons (Zhou et al. 2000; Shavali et al. 2008; Lee et al. 2001), over
expressing wild type and mutant Snca in BV-2 cells does not increase neurotoxicity or
promote cell death in BV-2 cells when cell viability was examined by activity of lactate
dehydrogenase (Rojanathammanee et al. 2011). This suggests intracellular Snca does
not intrinsically induce phenotypic change through cell toxicity but may regulate microglia
activation by inducing 2-AG levels. Furthermore, it is postulated that decreasing basal
microglia Snca levels in pathologic events such as PD may in fact have a negative
impact on the brains inflammation state by increasing microglia reactivity (Austin et al.
2011).
Because 2-AG levels may have an impact on microglia phenotype we
determined 2-AG levels in wild type, gene-ablated, and knock-in animals. Microwave
irradiation is crucial for determining basal 2-AG levels in mouse brain (Brose et al. 2016).
Non-microwave irradiated brain suggests a 200-fold higher basal level as compared to
microwaved brain thus microwave irradiation is required to determine basal 2-AG levels
in mouse brain. Snca gene-ablated mice have significantly higher basal levels of 2-AG
vs. wild type mice, which is consistent with the role of Snca in increasing PLC activity
(Austin et al. 2011). Interestingly, Snca gene-ablated mice expressing hSnca or mutant
Snca had only a partial reduction in 2-AG levels to basal wild type levels. Although data
from previous experiments linking Snca to Acsl activity for its impact on arachidonic acid
metabolism suggests Snca mutants will act like the null (Golovko et al. 2006a), the 2-AG
data in whole brain suggests that there may be a differential effect that is dependent on
the Snca mutation and that some activity is restored by the presence of hSnca and by
the Snca mutant knock-ins albeit not in its function in arachidonate Acsl mediated
metabolism. This indicates that not all functions of Snca in the mutant forms function as
82

the null. Others have suggested that mutations of Snca will lead to unique microglia
phenotypes which may explain our results (Kim et al. 2009; Rojanathammanee et al.
2011).
While Snca expression is unaffected by 3 hour LPS treatment in wild type mice,
there is a significant increase of 2-AG levels over basal levels in wild type brain. This
increase in whole brain 2-AG levels is exacerbated in Snca deficient mice suggesting
that Snca has a role in brain 2-AG levels during inflammation, but it was unexpected that
in the absence of Snca 2-AG would be elevated. Furthermore, there was not a
significant difference between basal 2-AG levels in Snca deficient mice and LPS
stimulated wild type mice, again suggesting that in Snca deficient mice 2-AG synthesis is
already at a stimulated level. It is interesting to note that 2-AG alone can drive microglia
to an alternative phenotype in vitro (Mecha et al. 2015) and may indicate a role in the
alternative phenotype as we have seen in Snca deficient microglia. Our findings
demonstrate decreased 2-AG levels from LPS treatment that resulted in a reduction in
Snca expression that may result in a reduction in recycling arachidonic acid having an
effect on 2-AG biosynthesis. The reduction in arachidonic acid recycling in the whole
brain may not only alter free arachidonic acid but arachidonic acid containing DAG as
well, but this possible mechanism needs to be further elucidated.
Because Snca gene-ablated mice had increased basal brain 2-AG levels and we
expected to find reduction due to reduced microglia phagocytic ability, we determined 2AG levels in primary microglia. Following LPS stimulation, there was a concomitant
reduction in released 2-AG levels and Snca expression after 12 hours. This suggest that
2-AG levels are altered possibly as an effect of reduced Snca expression in LPS
stimulated wild type primary microglia. Interestingly, 2-AG levels are not altered until 24
hours after LPS stimulation in Snca deficient primary microglia. This suggests that Snca
83

deficient primary microglia have altered 2-AG synthesis or degradation. A reduction in
CB2r stimulation results in an increase of microglia reactivity (Carlisle et al. 2002),
migration (Walter et al. 2003) and CB2r stimulation in microglia is neuroprotective in an
MPTP induced Parkinson’s disease (Chung et al. 2016). We see a decrease in 2-AG
that is the natural ligand for CB2r and due to this decrease may result in this reactive
phenotype.
Our previously published data determined that although Snca deficient microglia
have increased PLD2 expression to possibly compensate for reduced phagocytic ability
there is still a loss of phagocytic function (Austin et al. 2011). 2-AG regulates microglia
motility as CB2r is localized to the leading edge of activated microglia and stimulation by
2-AG results in extracellular signal-regulated kinase 1/2 activation (Walter et al. 2003).
This is important because the basal reduction found in Snca gene-ablated microglia as
well as the reduction of Snca in microglia following LPS stimulation may be a cause for
reduced microglia phagocytic ability. This is coupled with a significantly exacerbated
prostaglandin profile, where PGE2 is significantly increased over wild type microglia at
the same time of LPS stimulation. Others have shown that PGE2 stimulates COX-2 but
not COX-1 and PGE2 limits certain types of phagocytosis (Li et al. 2015; Keene et al.
2010; Nagano et al. 2010; Medeiros et al. 2009; Brock et al. 2008; Stachowska et al.
2007). Snca ablation in vivo increases palmitic acid turnover in choline
glycerophospholipids suggesting Snca has a role in inhibiting PLD activity (Golovko et al.
2006a). In conjunction with PLD2 tonic inhibition by Snca there may be some interplay
as phosphatidic acid can be metabolized into 2-AG. Our data supports the hypothesis
that Snca expression is linked to 2-AG release in primary microglia and may contribute
to regulating the phagocytic phenotype in vivo. However, further study is needed to
elucidate the discrepancy between basal brain 2-AG levels of Snca deficient mice and
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the greater response to LPS-stimulation of the Snca deficient brain with regards to 2-AG
formation. However, our data clearly support the hypothesis that Snca expression has a
significant role in microglial phenotype, supporting previous work demonstrating an
enhanced inflammatory response and a reduced phagocytic response in LPS treated
microglia from Snca deficient brains.
Our data shows that decreasing Snca expression may in fact have a negative
outcome in CNS inflammatory diseases such as Parkinson’s disease. Reduced ARA
recycling and increased eicosanoid synthesis following ischemia is consistent with
increased basal secretion of eicosanoids in Snca deficient microglia. Therefore,
reducing Snca expression may result in an increased inflammatory state of the microglia.
Furthermore, overexpression of Snca and Snca mutants in BV-2 cells did not result in
increased neurotoxic secretion (Rojanathammanee et al. 2011) suggesting that basal
levels of intracellular Snca may play a neuroprotective role acting as a molecular switch
in microglia, helping to enable the phenotypic shift from a proinflammatory to phagocytic
phenotype.
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CHAPTER IV
INTRODUCTION
Impact of alpha-synuclein on fatty acid metabolism during inflammatory response.

Snca ablation reduces palmitic acid (PAM, 16:0) and arachidonic acid (ARA,
20:4n-6) uptake in mouse astrocyte cultures and in whole brain in vivo, consistent with a
role in brain lipid metabolism. Although PAM incorporation and turnover is reduced in
most phospholipids by Snca ablation, there is a marked increase in PAM incorporation
and turnover in choline glycerophospholipids (ChoGpl). This is consistent with the tonic
inhibition of phospholipase D2 (PLD2) by Snca, because PLD2 selectively metabolizes
ChoGpl. Snca is also critical for ARA incorporation and turnover in brain phospholipids
due to a reduction in ARA-CoA formation. In microsomes from Snca ablated mice, ERlocalized Acsl activity towards ARA is decreased, but activity is restored by the addition
of physiological levels of either wildtype mouse or human Snca (hSnca). However,
addition of mutant forms of Snca (A53T and A30P) did not restore activity, suggesting
that mutant Snca functions similarly to the null. Although Snca has a robust impact on
lipid metabolism, lipid mediated signal transduction, and in neuroinflammation, it is
unknown if LPS treatment, inducing a neuroinflammatory response, in Snca geneablated mice will have a similar impact on ARA metabolism in the intact animal.
Because mutant Snca does not restore selective ARA-CoA Acsl activity and Snca
ablation results in enhanced PLD2 activity, our central hypothesis is that Snca geneablated mice will have an increased neuroinflammatory response due to reduced

86

ARA recycling and lack of PLD2 activity inhibition when compared to wild-type mice.
These studies will elucidate a fundamental function of Snca in vivo.
We propose a set of well-defined experiments using steady state kinetics of
radiolabeled fatty acid tracers to extend our studies of the role of Snca in lipid
metabolism and inflammation in vivo in SV/129 wild-type and Snca gene-ablated mice.
Our long-term goal is to understand the action of Snca on fatty acid metabolism as well
as its role in the inflammatory response. The objective of this study is to elucidate the
function in vivo of Snca in ARA metabolism using fatty acid radiotracers to study the role
of Snca in the inflammatory response induced by LPS treatment. We believe Snca has
a key role in fatty acid uptake and trafficking and our goal is elucidate its biological role
in downstream neuroinflammatory regulation via its influence on ARA metabolism,
offering insight into the pathophysiology of neuroinflammation.
Recent studies suggest Snca has a role in brain fatty acid metabolism. Snca
was thought to be a fatty acid binding protein (FABP) due to similar protein homology
and structure (Sharon et al. 2001), but its binding constants for fatty acids and its impact
on lipid metabolism is clearly different from classical FABP (Murphy et al. 2005; BarcelóCoblijn et al. 2007). However, like FABP (Murphy et al. 2005), Snca increases Acsl
activity, but is specific to ARA,(Golovko et al. 2006a). Furthermore, Snca deficiency
results in decreased PAM and ARA uptake, incorporation rate and fractional turnover in
phospholipids(Golovko et al. 2005; Golovko et al. 2006a). However, PAM incorporation
into choline glycerophospholipids (ChoGpl), a preferred substrate for PLD2, is increased,
while its incorporation and turnover into other major phospholipids is reduced (Golovko
et al. 2005). This is significant because it known that Snca tonically inhibits PLD2 activity
(Jenco et al. 1998; Outeiro and Lindquist 2003), which we have shown is critical in
enhancing neuroinflammatory response in Snca deficient microglia (Austin et al. 2006;
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Austin et al. 2011). Similarly, prostaglandin formation is increased following LPS
treatment or global ischemia as a result of dysfunctional ARA metabolism (Golovko and
Murphy 2008). Although Snca function has been studied in lipid metabolism, the
function Snca under inflammatory conditions in lipid metabolism is poorly understood.
While we have demonstrated previously the enhanced inflammatory response via ARA
metabolites in Snca ablated mice, how ARA metabolism is perturbed in vivo is unknown.
This work is significant because it will identify key roles of Snca in modulation of
neuroinflammatory response.
Snca facilitates PAM and ARA uptake in astrocytes (Castagnet et al. 2005) and
brain (Golovko et al. 2005; Golovko et al. 2006a), but it also has a role in brain neutral
lipid metabolism (Barceló-Coblijn et al. 2007). Using a steady-state kinetic model, it is
demonstrated that Snca deficiency reduces ARA incorporation and turnover in brain
phospholipids (Golovko et al. 2006a). This reduced ARA metabolism in Snca deficient
brain is the result of decreased Acsl activity, which is restored in vitro by adding
physiological levels of Snca (Golovko et al. 2006a). However, mutant forms of Snca fail
to restore this activity. Further, while we have identified a link between Snca deficiency
and enhanced PLD2 activity using PAM kinetic analysis and studies in microglia
cultures, the importance of Snca in the process is unknown. This work links Snca to
dysfunction in ARA metabolism resulting in an enhanced inflammatory response. This is
a major departure from the traditional ideas regarding Snca biology and will offer a better
fundamental understanding of how Snca ablation can modulate lipid mediated signal
transduction associated with neuroinflammation.
In this chapter, I determined the role of Snca in ARA uptake and trafficking in
brain and liver following 3 hours of LPS treatment. In the absence of Snca, there is a
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significant increase in the uptake of ARA into brain during LPS induced
neuroinflammation. Targeting to organic (lipid pools) and aqueous (β-oxidation)
fractions are increased during LPS-treatment, indicating more tracer is entering the Snca
deficient brain. However, fractional distribution into organic or aqueous fractions is not
affected. Incorporation into phospholipid pools in the Snca deficient mouse is increased,
consistent with the increase in the organic fraction. Consistent with the enhanced
incorporation into phospholipids, ARA trafficking into phosphatidylinositol and choline
glycerophospholipids are increased. We also found decreased targeting of ARA into
diacylglycerol suggests either an increase in DAG formation in brain of wild-type mice by
phospholipase C or greater utilization of DAG for phospholipid synthesis in brain of Snca
gene-ablated mice and may contribute to the increase in 2-AG levels found in whole
brain. These data suggest that during lipopolysaccharide-induced neuroinflammation
where ARA release is enhanced, Snca has a crucial role in maintaining ARA metabolism
into specific phospholipid pools utilized in lipid-mediated signaling.
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MATERIALS AND METHODS
Mice

This study was conducted in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals and under an animal protocol
approved by the University of North Dakota IACUC (Protocol 0708-1c). The wild type
mice used for the protocol were the 129/SvEv strain and the Snca gene-ablated mice
were generated by gene-targeted deletion of Snca (Cabin et al. 2002). Male mice were
age matched ~10 months old and were given standard laboratory chow and water ad
libitum.
Surgery, LPS treatment and Fatty Acid Infusion

Samples were collected from age matched (~9 month-old) SV/129 wild type or
Snca gene-ablated male mice (National Institute of Cancer, Frederick, MD) under an
approved protocol by the University of North Dakota (Grand Forks, ND) Animal Care and
Use Committee (protocol 0110-1). During catheter insertion mice were anesthetized
with (1-3%) isoflurane and polyethylene10 catheters were inserted into the right femoral
vein and artery. Because previously published data showed no difference in blood brain
barrier permeability between single does and divided doses of LPS (Jangula and Murphy
2013), we used a single dose of lipopolysaccharide (LPS) derived from E. coli 055:B5 J
(Sigma cat# L2880) dissolved in phosphate buffered saline (0.25 mg/mL). Mice were
injected with LPS (1 mg/kg) dose intraperitoneally (i.p.) post-surgery. Mice were allowed
to recover from anesthesia for three hours following surgery to allow equilibration of
metabolism following anesthesia (Murphy et al. 2004; Murphy et al. 2000b). At 3 h post
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LPS injection, mice were infused with 170 µCi/kg [1-14C]20:4n-6 at a rate of 50
µl/min for 10 min to achieve steady state plasma radioactivity. Blood was collected at
set intervals and plasma separated to assess intravascular radioactivity and confirm
steady state plasma radioactivity. Mice were then euthanized at 10 min with
pentobarbital (i.v.) and immediately subjected to head focused microwave irradiation to
heat denature enzymes in situ (Golovko et al. 2005; Murphy 2010). Whole brain, liver,
and heart were removed, flash frozen in liquid nitrogen, and then pulverized into a
homogeneous powder under liquid nitrogen conditions. Plasmas as well as whole blood,
because of the contribution of residual blood to tissue radioactivity, was extracted using
a two-phase extraction method (Folch et al. 1957) as previously described (Murphy et al.
2008). Residual blood in liver, heart, and brain was estimated to be 17, 22, and 2%,
respectively, based upon previously published data (Smith 1970; Regoeczi and Taylor
1978; Rosenberger et al. 2002; Rosenberger et al. 2003).
Tissue Lipid Extraction

Following pulverization, lipids were extracted from the tissues using a two-phase
extraction method (Folch et al. 1957). Powdered tissue was kept on dry ice until added
to a tared Tenbroeck homogenizer, to determine the mass (g ww) of the tissue added.
To the Tenbroeck homogenizer 17 vol. of chloroform and methanol (2:1, by vol) was
added. Once tissue was homogenized, the extract was removed, saved and then the
homogenizer was washed with 3 vol. of chloroform and methanol (2:1, by vol) and the
rinse added to the initial extract. The tissue residue was saved for protein quantification.
After homogenization, 4 vol of 0.9% KCl was added to extract, mixed by vortexing, and
allowed to separate into two phases overnight at -20°C under a N2(g) atmosphere. The
following morning, the top phase was removed and saved. To the lower phase, 4 vol. of
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chloroform, methanol, and water (3:48:47, by vol) was added, the sample vortexed,
chilled, and subjected to centrifugation to facilitate phase separation. The upper phase
was removed and combined with the previous upper phase to determine aqueous
fraction radioactivity using liquid scintillation counting (LSC). The lower phase was dried
down with N2 (g) and dissolved in hexane:2-propanol (3:2, by vol) and a portion used to
determine organic radioactivity using LSC. The unused portion was stored under N2(g)
atmosphere at -80°C in hexane:2-propanol (3:2, by vol).
Lipid Separation by Thin Layer Chromatography

Extracted lipids were separated using thin layer chromatography (TLC) on heatactivated (110°C) Whatman silica gel-60 plates. Neutral lipids were separated into
individual classes using petroleum either, diethyl ether, and acetic acid (75:25:1.3, by
vol.) (Marcheselli V.L. et. al. 1988). Phospholipids were separated into individual
classes using chloroform, methanol, acetic acid, and water (50:37.5:3:2, by vol.) (Jolly et
al. 1997). Lipids were visualized using iodine (phospholipids) or 6-(p-toluidino)-2naphthalenesulfonic acid (TNS) (neutral lipids) and identified using commercially
available standards (Avanti, Polar Lipids, Alabaster, AL). Once lipids were visualized,
the silica was scraped into glass scintillation vials and 0.5 mL ddH2O was added to
facilitate desorption of lipids from the silica. Then 10 mL of Scintiverse BD cocktail
(Fisher Scientific, Pittsburg, PA, USA) was added and samples were mixed by vortexing
and then allowed to settle for one hour. Samples were counted on a Beckman LS 6500
liquid scintillation counter equipped with low-level detection software (Fullerton, CA,
USA).
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PCR

Snca gene-ablation (neomycin-resistance gene- NeoR) and wild type Snca
expression was determined using PCR. Briefly, 20mg of brain tissue from infused mice
was extracted to obtain crude gDNA. Primers were chosen for Snca forward
(5’GGGTATTGATGGCTGCATCAGAG3’), Snca Reverse
(5’CACCAGCCTATCCAGGTTGAGTTC3’), NeoR (5’GATTGCACGCAGGTTCTCCG3’),
NeoR (5’CCAACGCTATGTCCTGATAG3’) amplification (Integrated DNA Technologies,
Coralville, IA, USA). Following extraction, GoTaq mastermix (Promega, Madison, WI)
was utilized with 1 µL each of forward and reverse primers (10 µM) to perform PCR.
Samples were denatured at 95°C for 3 min, followed by 35 cycles of 30 sec at 95°C, 30
sec at 54°C, and 1 min at 72°C, and ending with 5 min extension at 72°C. Samples
were then resolved on a 1% agarose gel containing 50 ug of ethidium bromide and
visualized on a ChemiDoc XRS+ UV light box (BioRad, Hercules, CA). Image analysis
was completed with Quantity One software (BioRad, Hercules, CA).
Protein Quantification

Protein content in the tissue residue was quantified using a modified dye-binding
assay utilizing bovine serum albumin as a standard (Bradford 1976). The tissue residue
was dried of residual solvent and then subject to hydrolysis with 0.2 KOH at 65°C
overnight (Murphy and Horrocks 1993). Samples were then mixed with dye binding
reagent and allowed to equilibrate for 10 min prior to reading on a spectrophotometer at
595 nm.
Statistics

Statistical analysis was done using Instat® statistical program (Graphpad, San
Diego, CA). Multiple comparisons were assessed using a one-way ANOVA with a
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Tukey-Kramer post hoc test, with p < 0.05 considered as significant, n=10-11. A twotailed Student’s t-test was used to determine significance between treatment groups,
with p < 0.05 considered to be significant, n=10-11.
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RESULTS
Plasma curves of [1-14C]20:4n-6 infused into wild type and Snca gene-ablated mice
are not different between groups

Because fatty acids are infused into animals based on weight it is important to quantify
how much tracer reaches plasma and that animals are reaching a steady state
concentration. Plasma is tested at several time points throughout the tracer infusion.
These data indicate that wild type and Snca gene-ablated mice received equal quantities
of infused radiotracer (Figure 31). To further quantify infused radiotracer, plasma curves
were integrated to determine area under the curve. There were was no difference found
between area under the curve of wild type (1634 +/- 263) or Snca gene-ablated (1436
+/- 336) mice (table 3). These data indicate that groups received equal quantities of
infused radiotracer.
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Figure 31. [1-14C]20:4n-6 tracer in plasma during 10 minute infusion. Organic plasma
curve of infused wild type (Snca +/+ filled circle) or Snca gene-ablated (Snca -/- unfilled
circle) mice over 10 minute infusion. Values represent means ± standard deviation
(n=10-11).

Plasma Curve (Area Under Curve)
Snca +/+ 1634 ± 263
Snca -/1436 ± 336
Table 3. Integrated plasma curve area. Integrated area under plasma curve of wild type
(Snca +/+) or Snca gene-ablated (Snca -/-) mice. Values represent means ± standard
deviation (n=10-11).
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PCR of brain tissue of wild type and Snca gene-ablated mice

Because previous data has shown that Snca deficient mice have reduced [1-14C]20:4n-6
uptake and incorporation into phospholipid pools, we confirmed the groups used in this
experiment by genotyping of the brain tissue. Due to the required time and effort of
mouse surgery and infusion only 3 – 4 mice may be infused per day and therefore
several groups of mice are required. To confirm our samples were not mislabeled, all
mice were genotyped but one mouse per surgery group is shown (Figure 32). As
expected, WT mouse brain expressed Snca while Snca gene-ablated mice did not
produce any bands corresponding to genomic Snca (Figure 32A). Inversely, the marker
gene after Snca gene-ablation, neomycin resistance gene (NeoR), was only expressed
in Snca gene-ablated mice (KO) (Figure 32B).

A

B
Figure 32. Tissue genotyping by PCR of mouse brain. An example of mouse Snca
gDNA expression in wild type (WT) or Snca gene-ablated mice (A). An example of
mouse NeoR gDNA expression in wild type (WT) or Snca gene-ablated mice (B).
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Snca gene-ablation reduces [1-14C]20:4n-6 uptake but not metabolic targeting into
brain

Following brain lipid extraction, radioactivity in organic and aqueous fractions was
determined. In Snca gene-ablated mice there was a significant increase in both organic
and aqueous fractions as compared to wild type mice (Figure 33). As expected there
was also a significant increase in the total (organic and aqueous fractions combined)
radioactivity. These data indicate more [1-14C]20:4n-6 tracer enters into both the organic
fraction, primarily representing incorporation into lipid pools, and into the aqueous
fraction, representing products of β-oxidation. Interestingly, there was no difference in
the fractional distribution of organic or aqueous fractions (Figure 34) suggesting
distribution into metabolic pools was not affected by Snca gene-ablation.
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Figure 33. [1-14C]20:4n-6 incorporation into organic and aqueous brain fraction in wild
type or Snca gene-ablated mice. The extent of [1-14C]20:4n-6 organic and aqueous
fraction incorporation into brain of wild type (Snca +/+) or Snca gene-ablated (Snca -/-)
mice following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent means ± standard
deviation (n=10-11). The asterisk indicates a statistically significant difference from wild
type (control) mice using Student’s t-test (p < 0.05).
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Figure 34. [1-14C]20:4n-6 fractional distribution into brain fraction in wild type or Snca
gene-ablated mice. The extent of [1-14C]20:4n-6 organic and aqueous fractional
distribution into brain of wild type (Snca +/+) or Snca gene-ablated (Snca -/-) mice
following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent means ± standard
deviation (n=10-11).
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[1-14C]20:4n-6 uptake and metabolic targeting in liver are not different between
groups

Because liver does not express Snca (Golovko et al. 2005) we used liver as a negative
control. Consistent with previously published data, Snca gene-ablation does not affect
uptake or metabolic targeting of [1-14C]20:4n-6 in the liver (Figure 35 and 36).
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Figure 35. [1-14C]20:4n-6 incorporation into organic and aqueous liver fraction in wild
type or Snca gene-ablated mice. The extent of [1-14C]20:4n-6 organic and aqueous
fraction incorporation into liver of wild type (Snca +/+) or Snca gene-ablated (Snca -/-)
mice following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent means ± standard
deviation (n=10-11).
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Figure 36. [1-14C]20:4n-6 fractional distribution into liver fraction in wild type or Snca
gene-ablated mice. The extent of [1-14C]20:4n-6 organic and aqueous fractional
distribution into liver of wild type (Snca +/+) or Snca gene-ablated (Snca -/-) mice
following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent means ± standard
deviation (n=10-11).

Total uptake into phospholipids and neutral lipids of [1-14C]20:4n-6 is altered
between groups in brain but not liver

After determining organic and aqueous fraction radioactivity, the organic fraction is
separated by column chromatography into neutral lipid and phospholipid pools. In the
brain there is a significant 1.4-fold increase in targeting into the phospholipid pool, but no
change in neutral lipids of Snca gene-ablated mice (Figure 37). Targeting to neutral
lipids and phospholipids is not significantly altered in liver (Figure 38), which is
consistent with the lack of any difference in the total organic fraction between groups.
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These data suggest that the increase in brain organic fraction is esterified into the
phospholipid pool.

Figure 37. [1-14C]20:4n-6 incorporation into brain neutral or phospholipids in wild type or
Snca gene-ablated mice. The extent of [1-14C]20:4n-6 incorporation into brain neutral
and phospholipids of wild type (Snca +/+) or Snca gene-ablated (Snca -/-) mice following
3h LPS (i.p. 1mg/kg) treatment. Values represent means ± standard deviation (n=1011). The asterisk indicates a statistically significant difference from wild type (control)
mice using Student’s t-test (p < 0.05).
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Figure 38. [1-14C]20:4n-6 incorporation into liver neutral or phospholipids in wild type or
Snca gene-ablated mice. The extent of [1-14C]20:4n-6 incorporation into liver neutral
and phospholipids of wild type (Snca +/+) or Snca gene-ablated (Snca -/-) mice following
3 h LPS (i.p. 1 mg/kg) treatment. Values represent means ± standard deviation (n=1011).

Esterification of [1-14C]20:4n-6 into neutral lipid and phospholipid fractions were
altered by Snca gene-ablation in brain

Snca gene-ablated mice had significantly increased radioactivity in the
phosphatidylinositol (PtdIns) and the choline glycerophospholipids (ChoGpl) in the brain,
which is consistent with the enhanced incorporation into brain phospholipids (Table 5).
Enhanced incorporation into PtdIns is noteworthy as it is a vital phospholipid involved
with PLC-mediated signal transduction and for 2-AG formation. The increase of [1103
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C]20:4n-6 into ChoGpl, a storage phospholipid for 20:4n-6 in the brain, suggests that

there is increased ChoGpl turnover during LPS induced inflammation and subsequent
increased incorporation of tracer in Snca gene-ablated mice. Consistent with previous
data, Snca ablation increases phospholipase D activity causing increased turnover of
ChoGpl, a PLD substrate (Golovko et al. 2006a). Snca gene-ablation reduced
diacylglycerol by 75% (Table 5), which could result from either a reduction in DAG
formation by phospholipase C or a greater utilization of DAG for phospholipid synthesis,
consistent with the increased phospholipid fraction.

k* x 10 -5 (sec-1)
WT
Mean

Fractional Dist. (%)

KO
STD

Mean

WT
STD

KO

Mean

STD

Mean

STD

DAG
FFA
TAG

0.22
3.40
0.45

0.23
1.20
0.37

0.06
4.58
0.80

0.10 *
2.17 ns
0.52 ns

5.3
84.0
11.2

5.6
29.7
9.1

1.0
84.3
14.7

1.8
40.0
9.5

Ptd2 Gro
EtnGpl
PtdIns
PtdSer
ChoGpl

0.09
0.97
3.67
0.32
6.35

0.12
0.46
0.67
0.31
0.76

0.06
1.11
4.85
0.49
7.78

0.09
0.54
1.02
0.43
1.11

0.8
8.5
32.2
2.8
55.7

1.0
4.0
5.9
2.7
6.7

0.4
7.8
34.0
3.4
54.5

0.7
3.8
7.1
3.0
7.8

ns
ns
*
ns
*

*
ns
ns

ns

ns
ns
ns
ns

* denotes significance p < 0.05 Student's unpaired, two-tailed t-test

Table 5. [1-14C]20:4n-6 incorporation into individual brain neutral or phospholipids in wild
type or Snca gene-ablated mice. The extent of [1-14C]20:4n-6 incorporation into brain
neutral lipids or esterification into phospholipids of wild type (Snca +/+) or Snca geneablated (Snca -/-) mice following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent
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means ± standard deviation (n=10-11). The asterisk indicates a statistically significant
difference from wild type (control) mice using Student’s t-test (p < 0.05).

Esterification of [1-14C]20:4n-6 into neutral lipid fractions were altered by Snca
gene-ablation but not into phospholipids in liver

Following separation of neutral lipids and phospholipids, samples are further separated
into individual lipid fractions. Tracer entering into free fatty acid and diacylglycerol pools
is significantly increased in Snca gene-ablated mice. Similar to previously published
results, Snca gene-ablation had no impact on tracer incorporation into liver
phospholipids.
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k* x 10 -5 (sec-1)
WT

Fractional Dist. (%)

KO

WT

Mean

STD

Mean

STD

Chol
DAG
FFA
TAG
CE

10.4
12.9
33.0
406.7
1.6

2.2
2.3
12.0
48.8
0.5

13.6
19.2
51.6
399.9
2.0

3.8
5.0
18.0
152.7
0.8

Ptd2 Gro
PtdOH
EtnGpl
PtdIns
PtdSer
ChoGpl
CerPCho
lysoPtdCho

8.5
7.0
23.4
18.5
135.3
135.3
3.1
14.6

5.6
2.6
10.2
7.0
56.7
56.7
1.3
8.0

11.8
4.7
23.6
18.1
136.0
136.0
3.4
15.3

7.7
1.8
12.8
9.6
62.1
62.1
2.0
8.9

KO

Mean

STD

Mean

STD

ns
*
*
ns
ns

2.2
2.8
7.1
87.6
0.3

0.1
0.5
2.6
10.5
0.1

2.8
3.9
10.6
82.2
0.4

0.8
1.0
3.7
31.4
0.2

ns
*
ns
ns
ns

ns

4.0
3.3
10.9
8.6
1.6
63.3
1.5
6.8

2.6
1.2
4.8
3.3
0.7
26.5
0.6
3.7

5.4
2.1
10.7
8.2
3.5
61.7
1.5
6.9

3.5
0.8
5.8
4.3
2.8
28.2
0.9
4.0

ns

ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
ns
ns
ns

* denotes significance p < 0.05 Student's unpaired, two-tailed t-test

Table 5. [1-14C]20:4n-6 incorporation into individual liver neutral or phospholipids in wild
type or Snca gene-ablated mice. The extent of [1-14C]20:4n-6 incorporation into liver
neutral lipids or esterification into phospholipids of wild type (Snca +/+) or Snca geneablated (Snca -/-) mice following 3 h LPS (i.p. 1 mg/kg) treatment. Values represent
means ± standard deviation (n=10-11). The asterisk indicates a statistically significant
difference from wild type (control) mice using Student’s t-test (p < 0.05).
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DISCUSSION

In this study, we applied a well-defined radiotracer steady-state kinetic model to
determine fatty acid uptake and turnover to determine if Snca ablation altered ARA
metabolism during neuroinflammation. Snca expression is known to affect brain fatty
acid uptake and trafficking into specific lipid pools, including increased ARA uptake and
incorporation by modulating ER-localized Acsl activity (Golovko et al. 2006a). Incubation
with wildtype, but not mutant forms of Snca protein restores Acsl activity to produce
ARA-CoA in microsomes isolated from Snca ablated mice (Golovko et al. 2006a).
Similarly, dysfunctional ARA metabolism in Snca ablated mice results in increased
prostaglandin biosynthesis (Golovko and Murphy 2008) suggesting a pivotal role of Snca
in the inflammatory response.
Snca has a role in the inflammatory response of microglia via modulation of lipid
mediated signaling pathways (Austin et al. 2006). Snca inhibits PLD activity in yeast
(Outeiro and Lindquist 2003) as well as in animal studies (Jenco et al. 1998). PLD
activity is essential for activation of microglia required for inflammatory response
including expression of key cytokines such as IL-1 and TNF-α (Austin et al. 2006; Austin
et al. 2011). Butanol treatment attenuated PLD-mediated generation of increased
cytokine secretion observed in Snca ablated microglia (Austin et al. 2011) suggesting
Snca has a direct effect on inflammation via PLD2 pathway. Hence, Snca is known to
affect ARA metabolism producing inflammatory metabolites as well as PLD2 activity
modulation, key players in lipid mediated signal transduction. In microglia, Snca
deficiency results in a basally reactive phenotype and secretory phenotype that was
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exacerbated following LPS stimulation (Rojanathammanee et al. 2011). Because Snca
increases eicosanoid synthesis and lipid mediated signaling, it is important to asses if
Snca modulates ARA metabolism in the presence of inflammatory response.
In the absence of Snca expression, brain ARA uptake as well as targeting to
organic and aqueous fractions are increased during LPS stimulation (Figure 33),
indicating more tracer is entering the Snca deficient brain. However, metabolic
distribution into organic or aqueous fractions is unaffected (Figure 34). These results
are consistent with the increased ARA uptake and trafficking to organic fractions of
dBcAMP stimulated astrocytes (Figure 1), which also had reduced Snca expression
(Figure 13). This is in contrast to ARA uptake and targeting into unstimulated Snca
deficient mice, where ARA uptake and targeting into brain organic fraction is reduced
while the aqueous fraction remained unchanged (Golovko et al. 2006a). This previous
study in unstimulated mice is consistent with other studies that observed a decrease in
the uptake and trafficking of 16:0 in Snca deficient unstimulated mouse brain (Golovko et
al. 2005)and astrocytes (Castagnet et al. 2005). Under inflammatory conditions, the lack
of Snca enhances ARA uptake and trafficking into fractions associated with lipidmediated signaling consistent with inflammatory response.
The incorporation into total phospholipids is increased in Snca gene-ablated
mice, suggesting enhanced phospholipid pool targeting (Figure 37). This is consistent
with increased targeting into phospholipids in dBcAMP treated astrocytes (Figure 4) due
to selective increased Acsl expression (Figure 10,11). However, due to decreased Acsl
activity in Snca deficient mouse brain that is not subjected to inflammation, other
mechanisms are anticipated. FABP bind and chaperon fatty acids which facilitates
uptake and targeting as well as affecting phospholipid metabolism (Binas et al. 1999;
Murphy et al. 2000a; Murphy et al. 2005). The brain has detectable protein levels of
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FABP3, FABP5, and FABP7 (Owada and Kondo 2003; Owada et al. 1996; Owada 2008;
Veerkamp and Zimmerman). FABP3 is expressed in the brain primarily in neurons, with
the highest expression in cortical layers, in hippocampus, and in dentate gyrus (Owada
et al. 1996; Sellner et al. 1995). FABP3 has a binding preference for n-6 fatty acids
(Hanhoff et al. 2002), suggesting that this protein may be involved in the increased
uptake and trafficking of ARA in brain (Murphy et al. 2005). Further study is needed to
elucidate the mechanism by which ARA uptake and trafficking into phospholipids is
regulated in the brain following LPS stimulation.
In the absence of Snca, there is a reduction in brain unesterified free fatty acid
mass (Sharon et al. 2003). While we did not determine free fatty acid mass we found a
significant increase in free fatty acid incorporation into stimulated Snca deficient liver but
brain incorporation was not changed suggesting Snca has a role in free fatty acid
trafficking at least in liver during the inflammatory response. There was no change in
incorporation into liver phospholipids which is consistent with previously published data
(Golovko et al. 2006a). Because Snca protein is not detected in the liver (Golovko et al.
2005), the increase in diacylglycerol and free fatty acid incorporation is possibly a result
of lipid alteration in systemic metabolism and requires further study.
Snca gene-ablated mice had significantly increased ARA trafficking into
phosphatidylinositol and choline glycerophospholipids in the brain and is consistent with
the enhanced incorporation into brain phospholipids (Table5). Both PtdIns and ChoGpl
contain high amounts of ARA. Increased trafficking into PtdIns may have a significant
impact on PLC mediated signaling events and may account for the increased 2-AG
formation in LPS treated Snca deficient brain (Figure 14). The increase of ARA
incorporation into ChoGpl, the initial storage phospholipid for ARA in the brain, suggests
that there is increased ChoGpl turnover during LPS induced inflammation and
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subsequent increased incorporation of tracer in Snca gene-ablated mice. Consistent with
previous data, Snca ablation increases phospholipase D activity causing increased
turnover of ChoGpl, a PLD substrate (Golovko et al. 2006a). Snca tonically inhibits PLD
and in Snca deficient microglia there is enhanced PLD activity and increased ARA
metabolism (Austin et al. 2006). In brain, Snca gene-ablation reduced diacylglycerol
which could result from either a reduction in diacylglycerol formation by PLC or a greater
utilization of diacylglycerol for phospholipid synthesis, consistent with the increased
phospholipid fraction.

This is important because ARA is the major polyunsaturated

fatty acid at the sn-2 position in EtnGpl and ChoGpl (Svennerholm 1968; Murphy 1984;
López et al. 1995).
In summary, these data suggest that during LPS-induced neuroinflammation
where ARA release is enhanced, Snca has a critical role in maintaining ARA metabolism
and trafficking and suggests that Snca affects lipid-mediated signaling events. This work
links Snca to dysfunction in ARA metabolism resulting in an enhanced inflammatory
response. Interestingly, when ARA metabolism is enhanced, in Snca deficient mice
there is an opposite effect on uptake and trafficking of ARA when compared to Snca
deficient mice at basal levels. Further study is required to determine the mechanism
behind this differential affect in ARA metabolism following LPS stimulation. This work
supports current data suggesting that Snca plays a significant role in maintaining ARA
homeostasis of the brain under neuroinflammatory conditions and further study on the
role of Snca on lipid metabolism in the brain is required.
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CONCLUDING REMARKS

I have used several model systems including primary cultured astrocytes and
microglia, Snca deficient and mutant knock-in mice, and a steady state-kinetic mouse
model to determine the role of Snca lipid-mediated signal transduction during
neuroinflammation. Herein, we have determined several major roles of Snca during
inflammation:
(i) Astrocytes play a vital role in brain lipid metabolism. Therefore, we

determined the impact of dBcAMP treatment on radiolabeled ARA and 16:0 uptake and
metabolism in primary cultured murine cortical astrocytes. In dBcAMP treated
astrocytes, total ARA uptake was increased 1.9-fold compared to control, while total 16:0
uptake was unaffected. dBcAMP treatment increased expression of Acsl3 (4.8-fold) and
Acsl4 (1.3-fold), which preferentially use ARA and are highly expressed in astrocytes,
consistent with the increase in ARA uptake. However, expression of Fabp5 and Fabp7
were significantly reduced by 25% and 45%, respectively. Acot7 (20%) was also
reduced, suggesting dBcAMP treatment favors acyl-CoA formation. dBcAMP treatment
enhanced ARA (2.2-fold) and 16:0 (1.6-fold) esterification into total phospholipids, but
the greater esterification of ARA is consistent with the observed uptake through
increased Acsl, but not Fabp expression. Although total 16:0 uptake was not affected,
there was a dramatic decrease in 16:0 in the free fatty acid pool as esterification into the
phospholipid pool was increased, which is consistent with the increase in Acsl3 and
Acsl4 expression. In summary, our data demonstrates that dBcAMP treatment
increases ARA uptake in astrocytes and this increase appears to
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be due to increased expression of Acsl3 and Acsl4 coupled with a reduction in Acot7
expression all of which occurs in the presence of reduced Snca expression.
(ii) Snca deficient mice have higher basal brain 2-AG levels compared to

wildtype and LPS stimulation further exacerbated 2-AG synthesis. Microglia isolated
from Snca gene-ablated mice have reduced phagocytic ability (Austin et al. 2006), while
having elevated levels of proinflammatory cytokines and eicosanoids. Because 2-AG, a
ligand of CB2 receptors, has an important role in microglia motility (Walter et al. 2003),
we examined its association with Snca expression. We treated Snca gene-ablated mice
with LPS, which increased brain 2-AG levels compared to control mice. In control mice,
brain Snca expression was unchanged 3 hours after LPS-treatment, although eicosanoid
levels were significantly elevated. Interestingly, Snca deficient mice had higher basal
brain 2-AG levels compared to control. The increase in basal and LPS-stimulated 2-AG
levels in Snca deficient mice could result from multiple pathways and/or cell types and
may be inherently linked to the observed increase in ARA incorporation into PtdIns
during inflammation in brains of Snca gene-ablated mice.
(iii) In microglia from control mice, LPS-treatment reduced 2-AG levels in the

medium at 12h to 24h but not at 6h when compared with non-stimulated microglia.
Concomitantly, Snca expression was reduced at 12h to 24h but not 6h after LPSstimulation. In Snca gene-ablated mice, LPS-treatment also reduced 2-AG levels in the
medium compared to non-treated Snca deficient microglia, but was delayed to 24h and
was not reduced to the same extent as control. Our data supports the hypothesis that
Snca expression is linked to 2-AG release in primary microglia and may contribute to
regulating the phagocytic phenotype in vivo. However, further study is needed to
elucidate the increase in basal brain 2-AG levels of Snca deficient mice and the greater
response to LPS-stimulation.
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(iv) Using Snca gene-ablated mice, we determined the impact of Snca on brain

ARA metabolism during LPS-induced inflammatory response in vivo using an
established steady-state kinetic model. In liver, no significant differences were observed
in ARA uptake or incorporation into lipid pools between groups. In Snca deficient mouse
brain, there was a significant 1.3-fold increase in ARA uptake. This indicated more ARA
entering the Snca deficient brain from plasma. In the organic fraction, there was a
significant 1.4-fold increase into total phospholipids in KO mice, accounted for by
increased incorporation into choline glycerophospholipids and phosphatidylinositol. In
neutral lipid pools, ARA incorporation into diacylglycerols was reduced 75% in KO mice.
Hence, under inflammatory conditions where ARA release is enhanced, Snca has a
crucial role in maintaining ARA metabolism, and in the absence of Snca results in
increased uptake and incorporation into lipid pools associated with enhanced lipidmediated signaling during neuroinflammatory response.
These data suggest that under inflammatory conditions where ARA release is
enhanced, Snca has a crucial role in modulating ARA metabolism, and the absence of
Snca results in increased uptake and incorporation into lipid pools associated with
enhanced lipid-mediated signaling during neuroinflammatory response. This work
supports current data suggesting that Snca plays a significant role in maintaining
homeostasis of the brain under neuroinflammatory conditions and further study on Snca
mechanistic action is warranted.
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APPENDICIES

Abbreviations

16:0, PAM, palmitic acid
18:2n-6, LNA, linoleic acid
20:4n-6, ARA, arachidonic acid
22:6n-3, DHA, docosahexaenoic acid
2-AG, 2-arachidonyl glycerol
6-ketoPGF1α, 6-keto Prostaglandin F1α
Acot7, Acyl-CoA thioesterase
Acsl, long-chain acyl-CoA synthetase
ApoE, apolipoprotein E
CerPCho, sphingomyelin
ChoGpl, choline glycerophospholipids
CNS, Central Nervous System
COX-1/2, Cyclooxygenase – 1/2
DAG, diacylglycerol(s)
dBcAMP, dibutyryl-cAMP
Endocannabinoid receptor (1/2) eCB1r
Endocannabinoid, eCB
EtnGpl, ethanolamine glycerophospholipids
FABP3, (Heart)- fatty acid binding protein 3
FABP5, (Epidermal)- fatty acid binding protein 5
FABP7, (Brain)- fatty acid binding protein 7
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FFA, free fatty acids
GPCR, G protein coupled receptor
hSnca, Human α-synuclein
IL-1, Interluken-1
IL-6, Interluken-6
KO, Snca gene ablated
LDLR, low-density lipoprotein receptors
LPS, lipopolysaccharide
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NeoR, Neomycin resistance gene
PD, Parkinson’s Disease
PGD2, Prostaglandin D2
PGE2, Prostaglandin E2
PGF2α, Prostaglandin F2α
PLA2, Phospholipase A2
PLC, Phospholipase C
PLD, Phospholipase D
PtdSer, phosphatidylserine
PtdIns, Phosphatidylinositol
PUFA, polyunsaturated fatty acids
SDHA, succinate dehydrogenase complex, subunit A, (flavoprotein)
Snca, α-synuclein
TAG, triacylglycerol(s)
TNF-α, Tumor necrosis facto
WT, Wild type
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